Curriculum Vitae
Arun Srivastava, Ph.D.
George H. Kitzman Professor of Genetics
Chief, Division of Cellular and Molecular Therapy
MAILING ADDRESS:
Division of Cellular and Molecular Therapy
Cancer and Genetics Research Complex
University of Florida College of Medicine
2033 Mowry Road, Room 492-A
Gainesville, FL 32611-3633
PHONE:
(352) 273-8259
FAX:
(352) 273-8342
E-MAIL:
aruns@peds.ufl.edu
aruns@ufl.edu
WEBSITE:
http://www.peds.ufl.edu/research/profiles/srivastava_a.asp
EDUCATION:
Ewing Christian College
University of Allahabad
Allahabad 211002
B. Sc.
1971
Department of Biochemistry
University of Allahabad
Allahabad 211002
M. Sc.
1973
Microbiology and Cell Biology
Indian Institute of Science
Bangalore 560012
Ph. D.
1979
RESEARCH AND ACADEMIC APPOINTMENTS:
March 1978 - June 1980:
Assistant Researcher
Laboratory of Animal Virology
Memorial Sloan Kettering Cancer Center
New York, NY 10021
July 1980 - July 1982:
Research Associate
Department of Immunology and Medical
Microbiology
University of Florida College of Medicine
Gainesville, FL 32610
August 1982 - July 1985:
Assistant Professor
Departments of Medicine and Biochemistry
University of Arkansas for Medical Sciences
Little Rock, AR 72205
1
August 1985 - June 1991:
Assistant Professor
Departments of Medicine and Microbiology &
Immunology
Indiana University School of Medicine
Indianapolis, IN 46202
July 1991 - June 1994:
Associate Professor
Departments of Medicine and Microbiology
& Immunology
Indiana University School of Medicine
Indianapolis, IN 46202
July 1994 – June 2004:
Professor
Departments of Microbiology & Immunology
and Medicine
Indiana University School of Medicine
Indianapolis, IN 46202
July 2004 – present:
George H. Kitzman Professor of Genetics and
Chief, Division of Cellular & Molecular Therapy
Departments of Pediatrics, Molecular Genetics
& Microbiology, Powell Gene Therapy Center,
University of Florida College of Medicine,
Gainesville, FL 32611
December 2004 – November 2011:
Assistant Director, University of Florida General
Clinical Research Center, Gainesville, FL 32610
PROFESSIONAL SOCIETIES:
1.
2.
3.
4.
5.
Member, American Association for the Advancement of Science
Member, Sigma Xi
Member, American Society for Microbiology
Member, American Society of Hematology
Member, American Society of Gene Therapy
HONORS AND AWARDS:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
U.P. State Government Merit Scholarship (1967-1969)
Dudgeon Memorial Medal (1970)
Coondoo Memorial Medal (1970)
Best All-Round Student Medal (1971)
Junior Research Fellowship, Department of Atomic Energy, Government of India
(1974-1975)
Senior Research Fellowship, University Grants Commission, Government of India
(1975-1978)
Sreenivasaya Memorial Medal (1979)
Medical Research Endowment Award, University of Arkansas for Medical Sciences
(1984-1985)
Overseas Conference Fund Travel Award, Indiana University (1989)
Established Investigator Award, American Heart Association (1990-1995)
Member, Scientific Advisory Board, Avigen, Inc. (1992-1995)
2
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
Member, Medical Advisory Board, Cancer Research Foundation of America (19922004)
Member, Sterling Whos' Who (1995-present)
Member, Interglobal Who's Who (1996-present)
Member, Scientific Advisory Board, Immusol, Inc. (1996-2004)
Member, Steering Committee, National Gene Vector Laboratories (1997-2000)
Sigma Xi Excellence in Scientific Publication Award (1997)
Member, Editorial Board, Gene Therapy and Molecular Biology (1998-present)
Member Editorial Board, Journal of Hematotherapy and Stem Cell Research (19992004)
Member, Medical Biochemistry Study Section, National Institutes of Health (19992003)
Member, Editorial Board, Virology (2001-2006)
Member, Editorial Board, Journal of Virology (2004-2012)
Member, Editorial Board, Gene Therapy (2004-2012)
Member, Editorial Board, Human Gene Therapy (2005-2012)
Member, Viral Gene Transfer Vectors Committee, American Society of Gene Therapy
(2005-2008)
Member, Stem Cell Scientific Advisory Committee, Department of Biotechnology,
Ministry of Science and Technology, Govt. of India (2006-2011)
Member, Editorial Board, Recent Patents on DNA and Gene Sequences (2006present)
Member, National Heart, Lung, and Blood Institute, Program Project Review
Committee, NIH (2007-2011)
Member, Scientific Review Board, Gene Therapy Resource Program, NHLBI, NIH
(2007-2017)
Member, Editorial Board, Journal of Chinese Integrative Medicine (2010-2014)
Honorary Professor and Advisor, Shenzhen Institute of Xiangya Biomedicine, Central
South University, Shenzhen, PR China (2010-present)
Executive Editor, Journal of Genetic Syndromes and Gene Therapy (2012-present)
Science Chair, Department of Biotechnology, Govt. of India. Centre for Stem Cell
Research, Christian Medical College, Vellore, (2012-2015)
University of Florida Research Foundation Professor (2013)
Children’s Miracle Network Scholar (2013)
TEACHING EXPERIENCE:
University of Arkansas for Medical Sciences:
1.
2.
3.
4.
5.
Biochemical Genetics course for graduate students - Seven 1.5 hr. lectures (1984)
Virology course for graduate students - Four 1.5 hr. lectures (1985)
Clinical correlations for medical students - Eighteen 2 hr. conferences (1984-1985)
Laboratory research for graduate students (David Beranek and Paul Rossby) - Two 6weeks rotations and supervision (1983-1984)
Summer research program (Joe Jeffers and Molly Rice) - Two 4-week research
supervision (1984)
Indiana University School of Medicine:
1.
2.
3.
Virology tutorial for medical students - Two 2 hr. tutorials (1985)
Virology tutorial for graduate students - One 2 hr. tutorial (1986)
Virology course for graduate students - Three 1.5 hr. lectures (1987)
3
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Laboratory research for graduate students (Yanshu Wang and Brian Reynolds) - Two
3-week rotations (1987)
Laboratory research for graduate student (Fu Niu) - One 4-week rotation (1988)
Virology tutorial for medical students - Two 2 hr. tutorials (1988)
Microbiology course for graduate students - One 2 hr. lecture (1988)
Laboratory research for graduate students (Piruz Nahreini, Natalie Yeager and Amy
Tomita) - Three 3-week rotations (1988)
Virology course for graduate students - Five 1.5 hr. lectures (1989)
Summer research for undergraduates (Michael Woody and Jonathan Mellette) - Two
8-week supervision (1989)
Laboratory research for graduate students (Thomas Whitten, Rodney Maze, David
Morgenstern and Benjawan Khuntirat) - Four 3-week rotations (1989)
Molecular Genetics course on Oncogenes and Anti-oncogenes for graduate
students (Course Director) - Fifteen 2 hr. lectures/discussions (1990)
Summer research for undergraduates (Michael Woody, Jonathan Mellette and
Nickiya Palmer) - Three 8-week supervision (1990)
Laboratory research for graduate students (Anne Quets, Burton Webb and Michael
Woody) - Three 3-week rotations (1991)
Virology course for graduate students - Three 1.5 hr. lectures (1991)
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 1991)
Summer research for medical student and undergraduates (Michael Leone,
Jonathan Mellette and Bayyinah Batts) - Three 8-week supervision (1991)
Microbiology course for nursing students - Five 1.5 hr. lectures (Fall, 1991)
Virology tutorial for medical students - Two 2 hr. tutorials (1991)
Laboratory research for graduate student (Angela Montel) - One 10-week rotation
(1992)
Laboratory research for undergraduate student (Rebecca Little) - (1991-1992)
Microbiology course for nursing students - Five 1.5 hr. lectures (Fall, 1992)
Virology tutorial for medical students - Two 2 hr. tutorials (1992)
Laboratory research for graduate students (Anuja John, Ihn Jang and Lorraine
Cramer) - Three 10-week rotations (1993)
Summer research for undergraduate student (Nagesh Jayaram) - One 6-week
supervision (1993)
Virology course for graduate students - Three 1.5 hr. lectures (1993)
Microbiology course for nursing students - Five 1.5 hr. lectures (Fall, 1993)
Laboratory research for graduate student (Dagmar Kube and Jacqueline Hobbs) Two 10-week rotations (1994)
Molecular Genetics course on Human Gene Therapy for graduate students (Course
Director) - Fifteen 2 hr. lectures/discussions (1994)
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 1994)
Summer research for undergraduate (Ajay Sreenath) and medical (Tina Pham)
students (1994)
Microbiology course for nursing students - Five 1.5 hr. lectures (Fall, 1994)
Laboratory research for graduate students (Cathryn Mah, John Scherer, Chandrika
Kurpad and Rema Ramani) - Four 8-week rotations (1995)
Virology course for graduate students - Three 1.5 hr. lectures (1995)
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 1995)
Microbiology course for nursing students - Five 1.5 hr. lectures (Fall, 1995)
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 1996)
Summer research for undergraduate student (Ellen Faber) - One 1-week supervision
(1996)
Microbiology course for nursing students - Five 1.5 hr. lectures (Fall, 1996)
4
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 1997)
Virology course for graduate students - Three 1.5 hr. lectures (1997)
Summer research for undergraduate (Theresa Malkowski) and high school (Shruti
Srivastava) students - Two 4-week supervision (1997)
Laboratory research for graduate students (Jonathan Hansen, Kelly Hiatt, Nick
Laribee and Abing Wang) - Three 8-week rotations (1997)
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 1998)
Summer research for undergraduate (Oscar Gadea) and high school (Laura
Conway) students – Two 4-week supervision (1998)
Laboratory research for graduate students (Samantha Ciccone and Dan Briere) Two 8-week rotations (1998)
Virology course for graduate students - Three 1.5 hr. lectures (1998)
Hematopoiesis course for graduate students - Two 2 hr. lectures/discussions (1999)
Laboratory research for undergraduate students (Rachel Hoffman and Ruby Long) Two 8-week rotations (1999)
Laboratory research for graduate students (Kristin Hall, Patrick O’Donnell, Marcus
Fields and Ying Zhou) – Four 8-week rotations (2000)
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 2000)
Hematopoiesis course for graduate students – Two 2 hr. lectures/discussions (2000)
Laboratory research for graduate students (Helena Spartz and Geling Li) - Two 8week rotations (2000)
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 2001)
Hematopoiesis course for graduate students – Two 2 hr. lectures/discussions (2001)
Laboratory research for graduate students (Yue Si and Brian Pondenis) - Two 8-week
rotations (2001)
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 2002)
Hematopoiesis course for graduate students – Two 2 hr. lectures/discussions (2002)
Virology course for graduate students - Four 1.5 hr. lectures/discussions (2002)
Cancer and Gene Therapy course for graduate students, Indiana University,
Bloomington - One 1 hr. lecture (2002)
Laboratory research for graduate students (Javier Rivera, Qi Xu, Njeri Maina and
Christopher Lux) - Four 8-week rotations (2003)
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 2003)
Laboratory research for undergraduate students (Jenny Haak and Ryan Meshulam)
- Two 8-week rotations (2003)
Laboratory research for graduate students (Ayele-Nati Ahyi and Juan Jiminez) - Two
8-week rotations (2003, 2004)
Microbiology course for nursing students - Five 1.5 hr. lectures (Spring, 2004)
Hematopoiesis course for graduate students – Two 2 hr. lectures/discussions (2004)
University of Florida College of Medicine:
1.
2.
3.
4.
5.
6.
Science of Clinical Research Course (GMS-6181) for physician-scientists – One lecture
(Fall, 2005)
Summer research for undergraduate student (Matt Kynes) - 8-week supervision (2005)
Summer research for undergraduate students (Ajay Antony, Mark Arcario) - 8-week
supervision (2005, 2006)
Laboratory research for graduate student (Tolunay Aydemir) - 8-week supervision
(2006)
Summer research for undergraduate students (Hiten Patel, Lisa Nguyen, Chauntelle
Carter) - 8-week supervision (2007)
Howard Hughes Medical Institute Science for Life undergraduate research program
(Bart Kachniarz, Matt Lisankie, Julius De’Souza, Jay Khambatti, Carolina Vac) (20075
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
2008)
IDP Course in Tumor Biology (GMS-6064) for graduate students – One lecture (Spring,
2009)
Laboratory research for graduate student (Stephan Jahn) - 8-week supervision (2007)
Laboratory research for graduate student (Chen Ling) - 8-week supervision (2008)
Laboratory research for graduate student (Lauren Drouin) - 8-week supervision (2009)
Laboratory research for graduate student (Amanda Herring) - 8-week supervision
(2010)
IDP Course in Tumor Biology (GMS-6064) for graduate students – One lecture (Spring,
2011)
IDP Course in Molecular Therapy (GMS-5905) for graduate students – One lecture
(Fall, 2012) [Course Co-Director]
IDP Course in Tumor Biology (GMS-6064) for graduate students – One lecture (Spring,
2013)
Laboratory research for graduate student (Nikea Aytes) - 6-week supervision (2014)
IDP Course in Molecular Therapy (GMS-5905) for graduate students – Two lectures
(Fall, 2014) [Course Director]
IDP Course in Tumor Biology (GMS-6064) for graduate students – One lecture (Spring,
2015)
SERVICE:
University of Arkansas for Medical Sciences:
1.
2.
3.
4.
Member, Graduate School Faculty (1982-1985)
Member, Graduate Student Advisory Committee: David Beranek and Michael West,
Department of Biochemistry (1983-1985)
Member, Animal Research Care Committee (1984-1985)
Member, Graduate Admissions Committee, Department of Biochemistry (1984-1985)
Indiana University School of Medicine:
1.
2.
3.
4.
5.
6.
7.
8.
9.
Member, Graduate School Faculty (1985-2004)
Member, Education and Curriculum Committee: Geriatrics/Gerontology Topics
Committee (1989-1990)
Member, Indiana University - Purdue University at Indianapolis Institutional Biosafety
Committee (1989-1994)
Member Graduate Student Advisory Committee: Piruz Nahreini (Chair), Michael
Woody (Chair), Dagmar Kube (Chair), Cathryn Mah (Chair), Chandrika Kurpad
(Chair), Jonathan Hansen (Chair), Catherine Carow, Thomas Whitten, Karen
Gerlach, Benjawan Khuntirat, Paul Hendrie, Rodney Maze, Burton Webb, Anne
Quets, John Ritchie, Chang Kim, Kelly Hiatt, Esra Toussaint, Samantha Ciccone, Kristin
Hall, Elizabeth Lehr, Ying Zhou, and Njeri Maina (Chair) (Department of Microbiology
& Immunology); Teresa Smolarek and Ruthanne Blough (Department of Medical &
Molecular Genetics); Mona Qulali, Xin Zhang and Chunmei Zhao (Department of
Biochemistry & Molecular Biology); Wei Zhang (Department of Anatomy)
Educational Representative, American Society for Microbiology (1989-1990)
Vice President, American Society for Microbiology - Indiana Branch (1990-1991)
President, American Society for Microbiology - Indiana Branch (1991-1992)
Member, Sigma Xi Admissions Committee (1992-1997)
Member, Project SEED (Science Education for the Economically Disadvantaged)
Committee (1992-1995)
6
10.
11.
12.
13.
14.
Member, Laboratory Animal Resource Center Advisory Committee (1994-1997)
Member, Faculty Recruitment Committee, Department of Microbiology and
Immunology (1997-2004)
Member, Graduate Education Policy Committee, Department of Microbiology and
Immunology (1997-2004)
Member, Promotion and Tenure Committee, Department of Microbiology and
Immunology (1997-2004)
Chairman, Promotion and Tenure Committee, Department of Microbiology and
Immunology (1998-2004)
University of Florida College of Medicine:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Member, Graduate School Faculty (2004-present)
Member, Graduate Student Research Advisory Committee: Christina Pacak,
Department of Molecular Genetics and Microbiology (2004-2006)
Member, Graduate Student Research Advisory Committee: Amy Chen, Department
of Neuroscience (2004-2009)
Member, Graduate Student Research Advisory Committee: Shyam Daya,
Department of Molecular Genetics and Microbiology (2005-2009)
Member, Graduate Student Research Advisory Committee: Jesse Kay, Department
of Biochemistry and Molecular Biology (2006-2010)
Member, Graduate Student Research Advisory Committee: Max Salganik,
Department of Molecular Genetics and Microbiology (2007-2014)
Member, Graduate Student Research Advisory Committee: Brittney Gurda,
Department of Biochemistry and Molecular Biology (2007-2010)
Member, Graduate Student Research Advisory Committee: Fikret Aydemir,
Department of Molecular Genetics and Microbiology (2007-present)
Chair, Graduate Student Research Advisory Committee: Chen Ling, Department of
Molecular Genetics and Microbiology (2008-2011)
Member, Graduate Student Research Advisory Committee: Brandon Sack,
Department of Molecular Genetics and Microbiology (2008-2012)
Member, Graduate Student Research Advisory Committee: Lawrence Tartaglia,
Department of Biochemistry and Molecular Biology (2009-2014)
Member, Graduate Student Research Advisory Committee: Robert Ng, Department
of Biochemistry and Molecular Biology (2009-2012)
Member, Graduate Student Research Advisory Committee: Lauren Drouin,
Department of Biochemistry and Molecular Biology (2009-2014)
Member, Graduate Student Research Advisory Committee: Laura Adamson,
Department of Psychiatry (2009-2014)
Member, Graduate Student Research Advisory Committee: Igor Ignatovich,
Department of Psychiatry (2009-2014)
Member, Graduate Student Research Advisory Committee: Harald Messer,
Department of Biochemistry and Molecular Biology (2010-2012)
Member, Graduate Student Research Advisory Committee: Renee Ryall,
Department of Molecular Genetics and Microbiology (2011-2014)
Member, Graduate Student Research Advisory Committee: Geoffrey Rogers,
Department of Molecular Genetics and Microbiology (2011-present)
Member, Graduate Student Research Advisory Committee: Shweta Kailasan,
Department of Biochemistry and Molecular Biology (2011-present)
Member, Graduate Student Research Advisory Committee: Janine Gilkes,
Department of Medicine (2011-present)
Member, Graduate Student Research Advisory Committee: Fernanda Guimaraes,
Department of Orthopaedics and Rehabilitation (2011-2014)
7
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
Member, Translational Science Advisory Committee, Clinical and Translational
Science Award (CTSA) (2007-2012)
Member, Research Advisory Committee, University of Florida College of Medicine
(2007-2011)
Invited Mentor, American Society of Gene and Cell Therapy, Philadelphia, PA (2012)
Member, Graduate Student Research Advisory Committee: Kyungah Maeng,
Department of Anatomy and Cell Biology (2012-present)
Member, Graduate Student Research Advisory Committee: Yuan Lu, Department of
Orthopaedics and Rehabilitation (2012-present)
Member, Graduate Student Research Advisory Committee: Bridget Lins, Department
of Biochemistry and Molecular Biology (2012-present)
Member, Graduate Student Research Advisory Committee: Lin-Ya Huang,
Department of Biochemistry and Molecular Biology (2012-present)
Member, Graduate Student Research Advisory Committee: George Marek, III,
Department of Medicine (2013-present)
Invited Mentor, American Society of Gene and Cell Therapy, Salt Lake City, UT (2013)
Invited Mentor, American Society of Gene and Cell Therapy, Washington, DC (2014)
Member, Graduate Student Research Advisory Committee: Nikea Aytes,
Department of Biochemistry and Molecular Biology (2014-present)
Member, Graduate Student Research Advisory Committee: Yong Shen, Genetics &
Genomics Graduate Program, Genetics Institute (2015-present)
PROFESSIONAL ACTIVITIES:
Clinical/Postdoctoral Fellows/Research Associates:
Current Position
Past:
1.
Mark A. Dayton, M.D., Ph.D. (1986-1987)
2.
Richard C. Lauer, M.D. (1986-1987)
3.
Hassan Ashktorab, Ph.D. (1988-1989)
4.
Nikhil C. Munshi, M.D. (1990-1992)
5.
Harsh Wardhan, Ph.D. (1990-1992)
6.
Shangzhen Zhou, M.D. (1990-1993)
7.
Feng Luo, M.D. (1992-1993)
8.
Pinku Mukherjee, Ph.D. (1995-1996)
9.
Xu-Shan Wang, M.D. (1992-1997)
10.
Ling-lin Li, M.D. (1993-1994)
8
Internal Medicine Associates,
Landmark Medical Center,
Bloomington, IN
Atlanta
Hematol./Oncol.
Associates, Atlanta, GA
Associate Professor, Howard
University, Washington, DC
Associate
Professor,
DanaFarber Cancer Center, Boston,
MA
Research Associate, Hoffman
LaRoche, Nutley, NJ
Senior
Research
Scientist,
Children’s
Hospital
of
Philadelphia, PA
Pathologist, University of Southern
California, Los Angeles, CA
Irwin Belk Professor, Department
of Biology, University of North
Carolina at Charlotte, Charlotte,
NC
Senior Scientist, Eli Lilly and Co.,
Indianapolis, IN
Senior Scientist, Eli Lilly and Co.,
11.
Selvarangan Ponnazhagan, Ph.D. (1992-1997)
12.
Sudhanshu Raikwar, D.V.M, Ph.D. (1997-1998)
13.
Lijuan Yang, M.D. (1998-1999)
14.
Benjawan Khuntirat, Ph.D. (1997-1999)
15.
Hyung-Joo Kwon, Ph.D. (1998-2000)
16.
Bailin Tan, M.D. (1999-2000)
17.
Mengqun Tan, M.D. (1998-2000)
18.
Andrew Turinsky, Ph.D., M.D. (1999-2001)
19.
Keyun Qing, M.D. (1995-2002)
20.
Lan Peng, M.D. (1996-1997)
21.
Baohui Zhao, M.D. (2002-2003)
22.
23.
Kirsten A. Weigel-Van Aken, M.D. (1997-2004)
Daniela Bischof, Ph.D. (2003-2004)
24.
Nitin Chouthai, M.D. (2005-2006)
25.
Ira Surolia, MD (2005-2006)
26.
Jianqing Wu, M.D., Ph.D. (2004-2006)
27.
Weihong Zhao, M.D., Ph.D. (2003-2006)
28.
Lourdes Andino, Ph.D. (2007-2008)
29.
Zongchao Han, M.D., Ph.D. (2005-2008)
9
Indianapolis, IN
Endowed
Professor
in
Experimental
Cancer
Therapeutics, Department of
Pathology,
University
of
Alabama, Birmingham, AL
Assist. Res. Sci., Dept. of Internal
Medicine, University of Iowa
Senior Scientist, Eli Lilly and Co.,
Indianapolis, IN
Chief, Molecular Biology Section,
US Armed Forces Research
Institute, Bangkok, Thailand
Associate
Professor,
Yonsei
University, Seoul, Korea
Research
Associate,
Indiana
University School of Medicine,
Indianapolis, IN
President, Shenzhen Institute of
Xiangya Biomedicine, Shenzhen,
China
Fellow, Albany Medical College,
Albany, NY
Senior Scientist, Eli Lilly and Co.,
Indianapolis, IN
Assistant Professor, University of
Massachusetts Medical School,
Worcester, MA
Postdoctoral
Fellow,
Indiana
University School of Medicine,
Indianapolis, IN
Law School, Jacksonville, FL
Assistant
Scientist,
Indiana
University School of Medicine,
Indianapolis, IN
Assistant Professor, Department of
Pediatrics,
Wayne
State
University, Detroit, MI
Fellow, National Institutes of
Health, Betheda, MD
Professor,
Department
of
Geriatrics,
Nanjing
Medical
University, Nanjing, P.R. China
Professor,
Department
of
Medicine,
Nanjing
Medical
University, Nanjing, P.R. China
Research
Scientist,
Medical
University of South Carolina,
Charleston, SC
Assistant Professor, Department of
Opthalmology, University of North
Carolina at Chapel Hill, Chapel
30.
Li Zhong, M.D. (2001-2009)
31.
Lyudmyla Glushakova, PhD (2006-2007)
32.
Giridhararao Jayandharan, Ph.D. (2007-2010)
33.
Angela Rivers, M.D., Ph.D. (2007-2010)
34.
Binbin Cheng, Ph.D. (2009-2010)
35.
Samantha Gee, M.D. (2008-2011)
36.
Katherine McGoogan, M.D. (2009-2011)
37.
Chen Ling, Ph.D. (2011-2012)
38.
Lina Wang, M.D., Ph.D. (2012-2013)
39.
Yuan Wang, M.D., Ph.D. (2011-2014)
Hill, NC
Director, Vector Core, Gene
Therapy Center, University of
Massachusetts Medical School,
Worcester, MA
Scientist, Eragen Biosciences,
Gainesville, FL
Associate
Professor,
Indian
Institute of Technology, Kanpur,
India
Assistant Professor, University of
Illinois at Chicago, Chicago, IL
Lecturer,
Second
Military
Medical University, Shanghai,
P.R. China
Assistant
Professor,
National
Children’s Hospital, Cincinnati,
OH
Assistant
Professor,
Nemours
Hospital, University of Florida,
Jacksonville, FL
Research
Assistant
Professor,
University of Florida, Gainesville, FL
Instructor,
Second
Military
Medical University, Shanghai,
China
Lecturer,
Second
Military
Medical University, Shanghai,
P.R. China
Present:
1.
2.
3.
4.
5.
George Aslanidi, Ph.D. (2010-present)
Chen Ling, Ph.D. (2012-present)
Yuanhui Zhang, M.D., Ph.D. (2014-present)
Yaneris Cortes-Colon, M.D.
Yinglu Feng, M.D., Ph.D.
Research Assistant Professor
Research Assistant Professor
Postdoctoral Fellow
Clinical Fellow
Postdoctoral Fellow
Graduate Students:
Past:
1.
Piruz Nahreini, M.S., Ph.D. (1988-1992)
(Esther L. Kinsley Best Thesis Award, 1992)
2.
3.
Michael J. Woody, M.S. (1990-1994)
Chandrika Kurpad, M.S. (1995-1997)
4.
Dagmar Kube, Ph.D. (1994-1997)
(Esther L. Kinsley Best Thesis Award, 1997)
Cathryn Mah, Ph.D. (1995-1998)
5.
10
Senior Lecturer, University of
Colorado Health Sciences
Center, Denver, CO
Attorney at Law, Indianapolis, IN
Research Associate, University of
Arizona, Tucson, AZ
Research Scientist, Mayo
Clinic, Rochester, MN
Visiting Scientist, University of
6.
Jonathan Hansen, Ph.D., M.D. (1998-2001)
7.
Njeri Maina, Ph.D. (2004-2008)
8.
Jared Silver, M.D., Ph.D. (2007-2008)
9.
Chen Ling, Ph.D. (2008-2011)
10.
Liujiang Song, Ph.D. (2010-2012)
11.
Yuanhui Zhang, M.D. (2013-2015)
12.
Zifei Yin, M.D. (2013-2014)
California at Irvine, Irvine, CA
Assiatant Professor, University of
North Carolina, Chapel Hill, NC
Fellow, University of Florida College
of Medicine, Gainesville, FL
Resident, University of Virginia
College
of
Medicine,
Charlottesville, VA
Research
Assistant
Professor,
University of Florida, Gainesville, FL
Lecturer,
Xiangya
University,
Changsha, China
Postdoctoral Fellow, University of
Florida, Gainesville
Postdoctoral
Fellow,
Second
Military
Medical
University,
Shanghai, P.R. China
Study Sections/Research Review Committees:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Member, American Heart Association - Indiana Affiliate, Indianapolis, IN, 1990-1993
Member, National Heart, Lung, and Blood Institute, National Institutes of Health SiteVisit Team, University of Iowa, Iowa City, 1992
Ad Hoc Member, Experimental Virology Study Section, National Institutes of Health,
Bethesda, 1992
Member, Special Review Committee, Gene Therapy for Cystic Fibrosis, National
Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, 1993
Member, Special Review Committee, Gene Therapy for HIV-1 Infection, National
Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
1993
Ad Hoc Member, Experimental Virology Study Section, National Institutes of Health,
Bethesda, 1994
Member, Special Emphasis Panel, Gene Therapy for Sickle-Cell Disease, National
Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, 1994
Reviewer, University of Arkansas for Medical Sciences VA-Merit Award, 1994
Reviewer, North Carolina Biotechnology Center Academic Research Initiation Grant,
1995
Member, National Cancer Institute, National Institutes of Health Site-Visit Team, Norris
Comprehensive Cancer Center, University of Southern California, Los Angeles, 1995
Member, National Institute of Child Health and Human Development, National
Institutes of Health Site-Visit Team, Kennedy Kreiger Institute, Johns Hopkins University
School of Medicine, Baltimore, 1996
Member, Special Emphasis Panel, National Heart, Lung, and Blood Institute, National
Institutes of Health, Bethesda, 1996
Reviewer, VA Merit Award, 1996
Reviewer, Jeffress Research Grant, NationsBank of Virginia, Richmond, 1996
Member, RFA Review Committee, Pathogenesis and Treatment of Cystic Fibrosis,
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes
of Health, Bethesda, 1996
Reviewer, Phase II Small Business Innovation Research Grant, National Institute of
Mental Health, National Institutes of Health, Bethesda, 1996
Ad Hoc Member, Medical Biochemistry Study Section, National Institutes of Health,
11
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
Bethesda, 1996
Member, National Center for Research Resources, National Institutes of Health SiteVisit Team, General Clinical Research Center, University of Southern California, Los
Angeles, 1996
Ad Hoc Member, Medical Biochemistry Study Section, National Institutes of Health,
Bethesda, 1996
Member, National Institutes of Health Site-Visit Team, General Clinical Research
Center, University of Florida, Gainesville, FL, 1996
Reviewer, Comprehensive Sickle-Cell Center grant applications, National Heart,
Lung, and Blood Institute, National Institutes of Health, Bethesda, 1997
Member, Special Emphasis Panel, Gene Transfer Principles for Heart, Lung, and Blood
Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health,
Bethesda, 1997
Member, Special Study Section Y, National Institutes of Health, Bethesda, 1997
Member, Special Emphasis Panel, National Institutes of Health, Bethesda, 1997
Reviewer, National Gene Vector Laboratory Grants, National Institutes of Health,
Bethesda, 1997
Member, Special Review Committee, Gene Therapy for Cystic Fibrosis, National
Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, 1998
Member, Special Review Committee, Gene Therapy Approaches for Blood and
Vascular Disease, National Heart, Lung, and Blood Institute, National Institutes of
Health, Bethesda, 1998
Member, Special Emphasis Panel, National Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of Health, Bethesda, 1998
Reviewer, Italian Association of Cancer Research grant, 1998; 2000
Member, Gene Therapy Core Centers Grants Review Committee, National Institute
of Diabetes and Digestive and Kidney Diseases, National Institutes of Health,
Bethesda, 1998
Member, Special Review Committee, Gene Therapy for Cystic Fibrosis, National
Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, 1998
Member, Special Review Committee, Gene Therapy Approaches for Blood and
Vascular Disease, National Heart, Lung, and Blood Institute, National Institutes of
Health, Bethesda, 1998
Reviewer, National Gene Vector Laboratory Grants, Indianapolis, IN, 1998
Reviewer, R01 Grant Application, National Heart, Lung, and Blood Institute, National
Institutes of Health, 1998
Member, Special Review Committee, Gene Therapy Approaches for Blood and
Vascular Disease, National Heart, Lung, and Blood Institute, National Institutes of
Health, Baltimore, MD, 1999
Ad Hoc Member, Medical Biochemistry Study Section, National Institutes of Health,
Bethesda, MD, 1999
Reviewer, National Gene Vector Laboratory Grants, Bethesda, MD, 1998
Member, Juvenile Diabetes Foundation International Site-Visit Team, University of
Pennsylvania, Philadelphia, PA, 1999
Member, National Institutes of Health Site-Visit Team, General Clinical Research
Center, University of Florida, Gainesville, FL, 2000
Reviewer, United States-Israel Binational Science Foundation Grant, 2000
Member, Special Emphasis Panel, Gene Therapy for Diabetes and its Complications,
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes
of Health, Bethesda, 2001
Chairman, Special Emphasis Panel, SBIR Grant Review, National Institutes of Health,
Bethesda, 2001
12
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
AAV Abstract Reviewer, American Society of Gene Therapy, 2002
Member, Advisory Committee, Gene Therapy of Leber Congenital Amaurosis,
National Eye Institute, National Institutes of Health, Bethesda, 2002-2004
Member, Special Emphasis Panel, Muscular Dystrophy Cooperative Research
Centers, National Institutes of Health, Bethesda, MD, 2003
Member, Special Review Panel, Gene Therapy of Cystic Fibrosis, National Heart,
Lung, and Blood Institute, National Institutes of Health, Bethesda, 2004
AAV Abstract Reviewer, American Society of Gene Therapy, 2004
Member, Special Review Panel, National Heart, Lung, and Blood Institute, National
Institutes of Health, Bethesda, 2004
Member, Review Committee, Children’s Miracle Network, Gainesville, FL 2004
Coordinating Reviewer, AAV Abstracts, American Society of Gene Therapy, 2005
Chair, Special Emphasis Panel, Programs of Excellence in Gene Therapy, National
Institutes of Health, Bethesda, MD, 2005
AAV Abstract Reviewer, American Society of Gene Therapy, 2006
Member, Program Project Grant Review Panel, National Heart, Lung, and Blood
Institute, National Institutes of Health, Bethesda, 2006
Member, National Heart, Lung, and Blood Institute, Program Project Review
Committee, National Institutes of Health, Bethesda, MD, 2007
Member, Scientific Review Board, Gene Therapy Resource Program, National Heart,
Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 2007
Coordinating Reviewer, AAV Abstracts, American Society of Gene Therapy, 2008
Member, Special Emphasis Panel ZRG1 IDM-R (04) M, National Institutes of Health,
Bethesda, 2008
Member, Special Review Panel ZRG1 IDM-Q (03) M, National Institutes of Health,
Bethesda, 2008
Member, Special Emphasis Panel ZRG1 BST-M (58), National Institutes of Health,
Bethesda, 2009
Member, Special Emphasis Panel ZNS1 SRB-S-22 (Muscular Dystrophy Centers),
National Institutes of Health, Washington, DC, 2010
Member, Special Emphasis Panel ZRG1 GGG-A (02) National Institutes of Health,
Bethesda, 2010
Member, Special Emphasis Panel, Centers of Research Translation Grants, ZAR1 KM
M1 1, National Institutes of Health, Bethesda, 2010
Member, Review Panel, Gene Therapy Resource Programs (ZHL1 CCT-B (02) 1; ZHL1
CCT-B (03) 1; ZHL1 CCT-B (04) 1, National Heart, Lung, and Blood Institute, National
Institutes of Health, Bethesda, 2011
Member, Special Emphasis Panel 2012/01 HLBP 1, National Heart, Lung, and Blood
Institute, National Institutes of Health, Bethesda, 2011
Member, Special Emphasis Panel 2012/01 HLBP Workgroup, National Heart, Lung,
and Blood Institute, National Institutes of Health, Bethesda, 2011
Member, National Heart, Lung, and Blood Institute, Program Project Review
Committee, National Institutes of Health, Bethesda, MD, 2012
Ad Hoc Member, Virology A Study Section, National Institutes of Health, Bethesda,
MD, 2012
Member, Review Panel, Centers of Excellence for Translational Research Stage 1
Review (2014/01 ZAI1 LR-M (J1), National Institutes of Health, Bethesda, MD, 2013
Member, National Heart, Lung, and Blood Institute, Program Project Review
Committee, National Institutes of Health, Bethesda, MD, 2013
Chair, National Heart, Lung, and Blood Institute, Program Project Review Committee,
National Institutes of Health, Bethesda, MD, 2013
Chair, National Heart, Lung, and Blood Institute, Program Project Review Committee,
13
72.
73.
National Institutes of Health, Bethesda, MD, 2013
Member, National Heart, Lung, and Blood Institute, Program Project Review
Committee, National Institutes of Health, Bethesda, MD, 2014
Member, National Heart, Lung, and Blood Institute, Program Project Review
Committee, National Institutes of Health, Bethesda, MD, 2015
Reviewer for Scientific Journals:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
American Journal of Respiratory Cellular and Molecular Biology
Archives of Biochemistry and Biophysics
BioTechniques
Blood
BMC Biotechnology
BMC Cancer
Breast Cancer Research and Treatment
British Journal of Haematology
Cancer Detection and Prevention
Cancer Gene Therapy
Cancer Research
Cell Biology International
Current Gene Therapy
Current Opinion in Molecular Therapy
European Journal of Haematology
Experimental Hematology
Expert Reviews in Molecular Medicine
Gene
Gene Therapy
Gene Therapy and Molecular Biology
Human Gene Therapy
International Journal of Cancer
Journal of Biological Chemistry
Journal of Chinese Integrative Medicine
Journal of Clinical Investigations
Journal of Experimental Medicine
Journal of Gene Medicine
Journal of General Virology
Journal of Hematotherapy and Stem Cell Research
Journal of Infectious Diseases
Journal of Leukocyte Biology
Journal of Medical Virology
Journal of Thrombosis and Haemostasis
Journal of Virological Methods
Journal of Virology
Molecular Cell
Molecular Therapy
Molecular Therapy Methods and Clinical Developments
Nature
Nature Biotechnology
Nature Cell Biology
Nature Medicine
Physiological Genomics
PLoS ONE
14
45.
46.
47.
48.
49.
50.
51.
52.
PLoS Pathogen
Proceedings of the National Academy of Sciences, USA
Proceedings of the Society for Experimental Biology and Medicine
Science Translational Medicine
Stem Cells
Tissue Engineering
Toxins
Virology
Invited Lectures:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Symposium on Aging, Retroviruses and Cancer. University of Arkansas for Medical
Sciences, Little Rock, AR (1983)
Symposium on Aging, Retroviruses and Cancer, University of Kansas Medical Center,
Kansas City, KS (1983)
Oakland University, Department of Biological Sciences, Rochester, MI (1985)
Symposium on Molecular Aspects of Aging and Cancer. 39th Gerontological Society
of America Meeting, Chicago, IL (1986)
Indiana State University, Department of Life Sciences, Terre Haute, IN (1987)
Indiana University School of Medicine, Department of Radiation Oncology,
Indianapolis, IN (1990)
Hyland Division, Baxter Healthcare Corporation, Duarte, CA (1990)
Indiana University-Purdue University at Indianapolis, Department of Biology,
Indianapolis, IN (1991)
The Castle Group Ltd., New York, NY (1992)
University of Arkansas for Medical Sciences, Arkansas Cancer Research Center, Little
Rock, AR (1992)
Avigen Inc., Alameda, CA (1992)
Arkansas Children's Hospital, Little Rock, AR (1992)
University of Rochester School of Medicine and Dentistry, Rochester, NY (1993)
Indiana State University, Department of Life Sciences, Terre Haute, IN (1993)
Northwest Center for Medical Education, Indiana University, Gary, IN (1993)
Indiana University, Department of Biology, Bloomington, IN (1993)
International Conference/Workshop on Cord Blood Transplantation/Biology, Indiana
University School of Medicine, Indianapolis, IN (1993)
Purdue University, Department of Chemistry, West Lafayette, IN (1994)
Louisiana State University, Department of Biochemistry & Molecular Biology,
Shreveport, LA (1994)
Workshop on Gene Therapy in Cystic Fibrosis, Williamsburg Conference, Williamsburg,
VA (1994)
University of Cincinnati, Children's Hospital Medical Center, Department of Pediatrics,
Cincinnati, OH (1994)
University of Colorado School of Medicine, Genetic Therapy Basic Science Course,
Aspen, CO (1994)
University of Miami, Department of Microbiology & Immunology, Miami, FL (1994)
Eli Lilly & Co., Lilly Research Laboratories, Indianapolis, IN (1995)
Ribozyme Pharmaceuticals Inc., Boulder, CO (1995)
First Conference on Stem Cell Gene Therapy: Biology and Technology, Chevy Chase,
MD (1995)
Seventh Annual Fanconi Anemia Scientific Symposium, Boston Children's Hospital,
Boston, MA (1995)
15
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
Applied Immune Sciences, Inc., Santa Clara, CA (1995)
Workshop on AAV Vectors: Gene Transfer into Quiescent Cells, National Institutes of
Health, Bethesda, MD (1995)
Plenary Lecture, International Conference on Eukaryotic Expression Vector System:
Biology and Applications, New Delhi, India (1996)
Chiron Corporation, Emeryville, CA (1996)
Immusol, Inc., San Diego, CA (1996)
Advances in Gene Therapy Symposium, Indiana University School of Medicine,
Indianapolis, IN (1996)
Eli Lilly & Co., Lilly Research Laboratories, Indianapolis, IN (1996)
Gene Therapy Symposium, University of Navarra, Pamplona, Spain (1996)
Centeon, Kankakee, IL (1997)
University of Illinois at Chicago, Section of Hematology/Oncology, Chicago, IL (1997)
Indiana University School of Medicine, Department of Biochemistry & Molecular
Biology, Indianapolis, IN (1997)
International Conference/Workshop on Cord Blood Transplantation/Biology, Indiana
University School of Medicine, Indianapolis, IN (1997)
Eli Lilly & Co., Lilly Research Laboratories, Indianapolis, IN (1997)
The American Society of Gene Therapy Inaugural Meeting, Seattle, WA (1998)
University of Alabama at Birmingham Gene Therapy Center, Birmingham, AL (1998)
Gene Therapy International Conference, Heraklion, Crete, Greece (1998)
Medical College of Ohio, Department of Biochemistry & Molecular Biology, Toledo,
OH (1999)
International Symposium on Transcription Assembly and Nucleic Acid-Protein
Interactions. Indian Institute of Science, Bangalore, India (1999)
Planning Meeting for Pre-Clinical Toxicology Study Design Issues for Development of
Gene Therapy of Rare Monogenic Diseases, Food and Drug Administration,
Bethesda, MD (1999)
University of Texas at Austin, Department of Molecular Genetics & Microbiology,
Austin, TX (1999)
Millennium Conference on Nucleic Acid Therapeutics. Clearwater Beach, FL (2000)
University of Delaware, Department of Biological Sciences, Newark , DE (2000)
Medical University of South Carolina, Department of Microbiology and Immunology,
Charleston, SC (2000)
Mount Sinai School of Medicine, Institute for Gene Therapy and Molecular Medicine,
New York, NY (2001)
Avigen, Inc., Alameda, CA (2001)
Weill Medical College of Cornell University, Institute of Genetic Medicine, New York,
NY (2001)
The American Society of Gene Therapy 4 th Annual Meeting, Seattle, WA (2001)
Memorial Sloan-Kettering Cancer Center, Department of Human Genetics, New
York, NY (2001)
Boston University School of Medicine, Department of Microbiology, Boston, MA (2001)
Cerus Corporation, Concord, CA (2001)
State University of New York at Stony Brook, Department of Molecular Genetics &
Microbiology, Stony Brook, NY (2001)
Milton S. Hershey Medical Center, Pennsylvania State University, Department of
Microbiology & Immunology, Hershey, PA (2001)
New York Medical College, Department of Microbiology & Immunology, Valhalla, NY
(2001)
Wayne State University, Department of Biological Sciences, Detroit, MI (2002)
University of Connecticut, Department of Molecular and Cell Biology, Storrs, CT (2002)
16
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
Binghamton University, State University of New York, Department of Biological
Sciences, Binghamton, NY (2002)
Public Health Research Institute, Newark, NJ (2002)
Binghamton University, State University of New York, Binghamton, NY (2002)
University of Arkansas for Medical Sciences, Arkansas Cancer Research Center, Little
Rock, AR (2002)
University of Arkansas for Medical Sciences, Department of Microbiology and
Immunology, Little Rock, AR (2002)
St. Louis University School of Medicine, Cancer Center, St. Louis, MO (2003)
St. Louis University School of Medicine, Cancer Center, St. Louis, MO (2003)
Research Corporation Technologies, Inc., Tucson, AZ (2003)
Mayo Clinic, Molecular Medicine Program, Rochester, MN (2003)
Mayo Clinic, Molecular Medicine Program, Rochester, MN (2003)
University of Florida, Department of Pediatrics, Gainesville, FL (2003)
University of Florida, Department of Pediatrics, Gainesville, FL (2003)
Meet the Expert, The American Society of Gene Therapy 6 th Annual Meeting,
Washington, DC (2003)
Miami University of Ohio, Department of Microbiology, Oxford, OH (2003)
University of California, Davis, 2nd Annual Gene Therapy Symposium for Heart, Lung,
and Blood Diseases, Davis, CA (2003)
University of Florida, Department of Pediatrics Grand Rounds, Gainesville, FL (2004)
University of Alabama at Birmingham, Department of Pathology, Birmingham, AL
(2004)
Medical University of South Carolina, Department of Microbiology and Immunology,
Charleston, SC (2004)
University of Florida, Department of Pharmaceutics, Gainesville, FL (2004)
University of Florida Shands Cancer Center, Topics in Cancer and Cell Biology,
Gainesville, FL (2005)
University of Florida, Program in Stem Cell Biology and Regenerative Medicine,
Gainesville, FL (2005)
University of Missouri at Columbia, Department of Molecular Microbiology and
Immunology, Columbia, MO (2005)
University of Missouri at Columbia, Department of Molecular Microbiology and
Immunology, Columbia, MO (2005)
The American Society of Gene Therapy 8th Annual Meeting, NIH Grants Workshop, St.
Louis, MO (2005)
The American Society of Gene Therapy 8th Annual Meeting, Scientific Symposium, St.
Louis, MO (2005)
University of Florida, Department of Biochemistry & Molecular Biology, Gainesville FL
(2006)
Beckman Research Institute of the City of Hope, Comprehensive Cancer Center,
Duarte, CA (2006)
Beckman Research Institute of the City of Hope, Division of Virology, Duarte, CA
(2006)
Stem Cell Research Forum of India, Department of Biotechnology, Govt. of India,
Bangalore, India (2007)
Christian Medical College, Department of Haematology, Vellore, India (2007)
Christian Medical College, Vellore, India (2007)
University of Florida Shands Cancer Center, Topics in Cancer and Cell Biology,
Gainesville, FL (2007)
University of Massachusetts School of Medicine, Worcester, MA (2007)
Gordon Research Conference on the Science of viral vectors: The host response to
17
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
viral infection, Ventura, CA (2008)
Genzyme Corporation, Framingham, MA (2008)
University of North Carolina at Chapel Hill, Gene Therapy Center, Chapel Hill, NC
(2008)
Children’s Hospital of Philadelphia, Program in Cellular and Molecular Therapeutics,
Phildelphia, PA (2008)
University of Florida Shands Cancer Center, Topics in Cancer and Cell Biology,
Gainesville, FL (2008)
Medical University of South Carolina, Department of Microbiology and Immunology,
Charleston, SC (2008)
University of North Carolina at Charlotte, Charlotte Research Institute Life Science
Research Guest Lecture Series, Charlotte, NC (2009)
Wayne State University, Karmanos Cancer Institute, Detroit, MI (2009)
The American Society of Gene Therapy 12 th Annual Meeting, Scientific Symposium,
San Diego, CA (2009)
Beckman Research Institute of the City of Hope, Comprehensive Cancer Center and
Department of Virology, Duarte, CA (2009)
International Society on Thrombosis and Haemostasis, Education Program of the XXII
Congress, Boston, MA (2009)
Cold Spring Harbor Meeting on In Vivo Barriers to Gene Therapy, Cold Spring Harbor,
NY (2009)
National Hemophilia Foundation’s Tenth Workshop on Novel Technologies and Gene
Transfer for Hemophilia. University of North Carolina at Chapel Hill (2010)
Second Military and Medical University, Shanghai, PR China (2010)
Nanjing Medical University, Nanjing, PR China (2010)
True Busy Group, Shenzhen, PR China (2010)
Shenzhen Institute of Xiangya Biomedicine, Shenzhen, PR China (2010)
Taiwan-ACGA 2010 International Conference on Genetic and Genomic Medicine,
Academia Sinica, Taipei, Taiwan (2010)
University of Florida, Department of Biochemistry & Molecular Biology, Gainesville FL
(2011)
The American Society of Gene and Cell Therapy 14th Annual Meeting, Scientific
Symposium, Seattle, WA (2011)
University of Florida Genetics Institute, Gainesville, FL (2011)
Nippon Medical School, Department of Biochemistry and Molecular Biology, and
Division of Gene Therapy Research Center for Advanced Medical Technology,
Tokyo, Japan (2011)
Jichi Medical University, Division of Genetic Therapeutics, Center for Molecular
Medicine, Tochigi, Japan (2011)
University of Florida, Department of Molecular Genetics & Microbiology, Gainesville
FL (2011)
University of Florida Genetics Institute Scientific Advisory Board, Gainesville FL (2012)
University of Florida, Department of Pediatrics Faculty Research Seminar, Gainesville
FL (2012)
German Cancer Research Center, Symposium on Biology and Clinical Application
of Adeno-Associated Viruses, Heidelberg, Germany (2012)
Bayer Hemophilia Awards Program, Paris, France (2012)
University of Florida, Department of Medicine, Gainesville FL (2013)
Leading Edge Lecture, Irell and Manella Graduate School of Biological Sciences,
Beckman Research Institute of the City of Hope, Duarte, CA (2014)
Griffin Scecurities, Jacksonville, FL (2014)
Agilis Biotherapeutics, New York, NY (2014)
18
128.
129.
130.
131.
132.
133.
University of Florida Health Shands Cancer Center, Topics in Cancer, Gainesville FL
(2014)
EDITAS Medicine, Cambridge, MA (2014)
University of Florida, Department of Medicine Grand Rounds, Gainesville, FL (2014)
University of Florida, Department of Molecular Genetics & Microbiology, Gainesville
FL (2014)
Switch Bio Therapeutics, Boston, MA (2014)
Found Animals Foundation, Los Angeles, CA (2015)
Scientific Sessions Chaired/Co-Chaired:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
American Society for Microbiology - Indiana Branch Annual Meeting, Indianapolis, IN
(1990)
VIth Parvovirus Workshop, Montpellier, France (1995)
International Conference on Eukaryotic Expression Vector System: Biology and
Applications, New Delhi, India (1996)
American Society of Gene Therapy 5th Annual Meeting, Boston, MA (2002)
IXth Parvovirus Workshop, Bologna, Italy (2002)
American Society of Gene Therapy 7th Annual Meeting, Minneapolis, MN (2004)
American Society of Gene Therapy 9th Annual Meeting, Baltimore, MD (2006)
XIth Parvovirus Workshop, Les Diablerets, Switzerland (2006)
XII Parvovirus Workshop, Cordoba, Spain (2008)
XIII Parvovirus Workshop, Helsinki, Finland (2010)
American Society of Gene and Cell Therapy 14th Annual Meeting, Seattle, WA (2011)
Convener, Parvoviruses, XVth International Congress of Virology, Sapporo, Japan
(2011)
XVIth Parvovirus Workshop, Bordeaux, France (2014)
CONSULTANT:
1.
2.
3.
4.
Hyland Division, Baxter Healthcare Corporation, Duarte, CA (1990-1993)
Avigen, Inc., Alameda, CA (1992-1995)
Ribozyme Pharmaceuticals, Inc., Boulder, CO (1995)
Switch Bio, Boston, MA (2014-present)
PATENTS:
1.
2.
3.
4.
5.
6.
7.
U.S. Patent No. 5,252,479. Safe Vector for Gene Therapy, issued on October 12, 1993
U.S. Patent No. 6,521,225. AAV Vectors, issued on Feb. 18, 2003
U.S. Patent No. 7,052,692. Role of Tyrosine Phosphorylation of a Cellular Protein in
Adeno-Associated Virus 2-Mediated Transgene Expression, issued on May 30, 2006
U.S. Patent No. 8,445,267. Tyrosine-Modified Recombinant Adeno-Associated Virus
Vector Compositions and Methods of Use, issued on May 21, 2013
U.S. Patent No. 8,492,344. Targeting the PDK2-DCA Binding Pocket for Novel Cancer
Therpies, issued on Sep. 21, 2013
U.S. Patent No. 8,802,440. Therapeutic Methods based on Tyrosine-Substituted,
Capsid-Modified rAAV Vectors, issued on August 12, 2014.
Methods and Compositions for Liver-Specific Delivery of Therapeutic Molecules Using
19
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Recombinant AAV Vectors, filed on Sep. 11, 1996
Chimeric Parvovirus-Based Recombinant Vector System that Specifically Targets the
Erythroid Lineage, filed on Oct. 8, 1998
Role of Human Fibroblast Growth Factor Receptor 1 as a Co-Receptor for Infection
by Adeno-Associated Virus 2, filed on Dec. 31, 1998
Serine/Threonine-Modified
Recombinant
Adeno-Associated
Virus
Vector
Compositions and Methods of Use, filed on May 15, 2011
AAV vectors with high transduction efficiency and uses thereof for gene therapy,
filed on March 15, 2013
Improved RAAV Vectors and Methods for Transduction of Photoreceptors and RPE
Cells, filed on March 4, 2014
Genome-Modified Recombinant AAV Vectors, filed on November 21, 2014
Recombinant AAV1, AAV5, and AAV6 Capsid Mutants and Uses Thereof, filed on
February 3, 2015
Recombinant AAV-Parvovirus B19 Hybrid Vectors for Gene Therapy of Human
Hemoglobinopathies, to be filed on February 19, 2015
Site-Specific Integrating Recombinant AAV Vectors for Human Hematopoietic Stem
Cell Transduction, to be filed on February 19, 2015
A Simple Method to Achieve High-Efficiency Transduction of Human Hematopoietic
Stem Cells by Recombinant AAV Vectors, to be filed on February 19, 2015
Strategies to Achieve High-Titer, High Potency Recombinant AAV Serotype Vectors,
to be filed on February 19, 2015
Development of Chimeric AAV6-B19 Vectors for in vivo Targeting of Human
Hematopoietic Stem Cells, to be filed on February 19, 2015
Novel Recombinant AAV3 Serotype Vectors for Gene Therapy of Human Liver
Cancers, to be filed on February 19, 2015
GRANTS, FELLOWSHIPS AND AWARDS:
Previously funded:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
Biomedical Research Support Grant RR-05350-20, University of Arkansas for Medical
Sciences. "Studies on gene expression during aging:
Primary structure and
transcription analysis of specific sequences." $5,000. 1983 - 1984
Medical Research Endowment Grant, University of Arkansas for Medical Sciences.
"Proto-oncogenes, tyrosine kinases and cellular aging. "$4,400. 1984 – 1985
American Cancer Society Institutional Grant, Indiana University School of Medicine.
"Molecular correlates of cancer, cellular growth and differentiation: Role of cellular
proto-oncogenes." $5,000. 1986 - 1987
American Heart Association Grant-in-Aid, Indiana Affiliate. "Studies on normal cellular
growth control." $28,000. 1987 – 1989
SUR Award. Indiana University-Purdue University at Indianapolis. "Parvoviruses and
human disease." $1,000. 1989
Overseas Conference Fund Travel Award, Indiana University. "EMBO Workshop on the
molecular biology of parvoviruses." Jerusalem, Israel. $600. 1989
NIH Grant AR-20582, Indiana University-Multipurpose Arthritis Center. "The human
parvovirus B19 and rheumatoid arthritis". $93,775. 1989 – 1991
American Heart Association - Indiana Affiliate, Grant-in-Aid. "Molecular correlates of
human parvoviruses and cytotoxicity". $50,000. 1991 - 1993
NIH Grant R29 AI-26323, "Studies on the human parvovirus B19." $349,927. 1988 – 1994
Vestmark, Inc. "Gene therapy with human parvovirus vectors". $601,474. 1992 - 1995
American Heart Association - Established Investigator Award. "Molecular genetics of
20
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
the human parvovirus B19". $175,000. 1990 - 1995
Ribozyme Pharmaceuticals Inc. "AAV vectors for gene transfer." $48,000. 1995 – 1996
NIH Grant R01 HL-48342, "Parvovirus-mediated gene transfer in human stem cells".
$887,175. 1992 – 1997
NIH Grant P50 DK-49218. Centers of Excellence in Molecular Hematology (P.D.: David
A. Williams, M.D.). "Adeno-associated virus 2-mediated transduction of
hematopoietic stem and progenitor cells". $328,682. 1994 - 1999
NIH Grant P01 HL-53586. Gene replacement therapy in hematopoietic stem cells
(P.D.: Mary C. Dinauer, M.D., Ph.D.). "Adeno-associated virus 2-mediated
transduction of hematopoietic stem and progenitor cells". $601,000. 1994 – 1999
NIH Grant U42 RR-11148. "National Gene Vector Laboratory at Indiana University"
(P.D.: Kenneth G. Cornetta, M.D.). $3,010,280. 1995 – 2000
Chiron Corporation. "Adeno-associated virus-based vectors for gene therapy".
$600,000. 1997 – 2000
NIH Grant 1R01 HL-58881-04. "Parvovirus vectors for human gene therapy".
$1,059,676. 1997 – 2001
Phi Beta Psi Sorority Grant. "Human parvoviruses, aging and cancer." $94,800. 1987 2002
NIH Grant T32 HL-07910-05. "Basic science studies on gene therapy of blood diseases".
$939,925. 1999 - 2004
NIH Grant P30 CA-82709-05. “Indiana University Cancer Center”. (P.D.: Stephen
Williams, M.D., Hematopoiesis Program Leader, Hal E. Broxmeyer, Ph.D.). $6,012,125.
1999 - 2004
NIH Grant T32 DK-07519-16. "Regulation of hematopoietic cell production". (P.D.: Hal
E. Broxmeyer, Ph.D.). $2,324,732. 2000 - 2005
NHLBI Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases.
“Recombinant human parvovirus vector-mediated gene transfer in fetal monkeys”.
$30,000 [at University of California, Davis]. 2003 - 2004
NIH Grant R01 EB-002073-08. "Parvovirus vectors for human gene therapy".
$1,250,000. 2001 - 2006
NIH Grant R01 HL-65570-06. “Hematopoietic stem cell transduction by AAV vectors".
$1,000,000. 2001 - 2007
Florida Department of Health - Bankhead-Coley Cancer Research Program Shared
Instrument Grant. “Fluorescence-Activated Cell Sorter”. $499,980. 2007 - 2007
Howard Hughes Medical Institute - University of Florida Science for Life for
Undergraduate Student [Bart Kachniarz]. $2,500. 2007 - 2008
St. Baldrick’s Foundation. “Development of targeted therapy of infant leukemia“.
(Fellowship for Angela Rivers, M.D., Ph.D.). $112,030. 2008 – 2010
NIH Grant R01 HL-076901-06. “Human parvovirus B19 vectors: Mechanism of
transduction”. $1,250,000. 2004 - 2010
NIH Grant P01 DK-058327-10. “Recombinant AAV for correction of genetic
abnormalities”. (PD: Barry J. Byrne, M.D., Ph.D.). $1,269,063. 2005 - 2011
NIH Grant M01 RR-00008-43. “University of Florida General Clinical Research Center”.
(PI: M.L. Good, MD). $24,563,801. 2006 - 2011 [Asst. Prog. Dir.]
Bayer Hemophilia Special Award. “Development of novel AAV vectors and
strategies for the potential gene therapy of hemophilia A”. $200,000. 2010 - 2012.
[Principal Investigator]
Currently active/pending [Direct costs only]:
21
1.
Kitzman Endowment, University of Florida Foundation. Research support for Dr.
Srivastava. $73,367 per year. July 1, 2004 – Recurrent
2.
NIH Grant 1R01 HL-097088-04. “Next generation of recombinant AAV serotype
vectors for gene therapy". $2,244,687. July 1, 2010 - March 31, 2015. [Contact
Principal Investigator]
3.
NIH Grant 1R21 EB-015684-01. “Safety and efficacy of optimized AAV3 vectors in
murine and NHP livers". $275,000. September, 2012 - August, 2015. [Contact Principal
Investigator]
4.
Bankhead-Coley Cancer Research Program. “Treatment for human hepatocellular
carcinoma based on genome- and capsid-optimized recombinant adenoassociated virus serotype 3 vectors". (PI: C. Ling, PhD). $374,000. July 1, 2012 - June
30, 2015. [Co-Investigator]
5.
NIH Grant T32 DK-074367-06. “Regenerative Medicine Training Grant”. [P.D.: Edward
Scott, Ph.D. $1,500,000. December, 2012 - November 30, 2017. [Preceptor]
6.
NIH Grant 1R01 HL-097088-05A1. “Next generation of recombinant AAV serotype
vectors for gene therapy". $2,521,615 [Requested]. April 1, 2015 - March 31, 2020.
[Principal Investigator]
Note: This application received a Prioriy Score in the 9th percentile [The current Payline is in
the 11th percentile].
7.
NIH Grant 1R41 AI-118154-01A1. “Development of optimized AAV serotype vectors
for human gene therapy“. $219,733 [Requested]. July 1, 2015 - June 30, 2016
[Principal Investigator]
Note: The A0 version of this application received an Impact Score of 39 [Possible Payline is
35].
8.
NIH Grant P01 HL-051811-20A1. “Gene and pharmacological therapies for cystic
fibrosis”. (PD: William B. Guggino, Ph.D.). Project 4 – „Biology of adeno-associated
viral vectors (Srivastava, PI). $1,655,815 [To be requested]. December, 2015 –
November, 2020. [Principal Investigator, Project 4]
Note: Project 4 received an Impact Score of 19].
9.
NIH Grant 2R01 HL-065570-06A1. “Hematopoietic stem cell transduction by AAV
serotype vectors". $1,250,000 [To be requested]. December, 2015 - November, 2020.
[Principal Investigator]
10.
NIH Grant 1R01 CA-160720-01A1. “Optimized AAV3 serotype vectors for the potential
gene therapy of liver cancer". $1,250,000 [To be requested]. December, 2015 November, 2020. [Principal Investigator]
PUBLICATIONS:
Peer-Reviewed Manuscripts:
1.
C. Ling, Y. Wang, Y. Lu, L. Wang, G.R. Jayandharan, G.V. Aslanidi, B. Li, B. Cheng, W.
Ma, T. Lentz, C. Ling, X. Xiao, R.J. Samulski, N. Muzyczka, and A. Srivastava. Enhanced
transgene expression from recombinant single-stranded AAV vectors in human cell
22
2.
lines in vitro and in murine hepatocytes in vivo. J. Virology, 89: 952-961, 2015.
Y. Zhang, L, Wang, Y. Lu, G.V. Aslanidi, A. Srivastava, C. Ling, and C. Ling. Cytotoxic
genes from traditional Chinese medicine inhibit tumor growth both in vitro and in
vivo. J. Int. Medicine, 12: 483-494, 2014.
3.
C. Ling, Y. Wang, Y. Zhang, A. Ejjigani, Z. Yin, Y. Lu, L. Wang, M. Wang, J. Li, Z. Hu, G.V.
Aslanidi, L. Zhong, G. Gao, A. Srivastava, and C. Ling. Selective in vivo targeting of
human liver tumors by optimized recombinant AAV3 vectors in a murine xenograft
model. Human Gene Therapy, 25: 1023-1034, 2014.
4.
R.B. Batchu, O.V. Gruzdyn, A.M. Marino-Bost, S. Szmania, G. Jayandharan, A.
Srivastava, B.K. Kolli, D.W. Weaver, F. van Rhee, and S.A. Gruber. Efficient lysis of
epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using
rAAV-6 capsid mutant vector. Vaccine, 32(8): 938-943, 2014.
5.
M.-J. Chen, Y. Lu, K.E. Erger, T.J. Conlon, E. Ahmed, L. Hong, M.L. Brantly, A. Srivastava,
W.W. Hauswirth, N. Terada, C. Yao, T. Hamazaki, and S. Song. Reprogramming
adipose tissue derived mesenchymal stem cells (AT-MSCs) into pluripotent stem cells
by a mutant AAV vector. Hum. Gene Therapy Methods, 25: 72-82, 2014.
6.
E. Ten, C. Ling, Y. Wang, A. Srivastava, L. Dempere, and W. Vermerris. Templatesynthesized lignin nanotubes as vehicles for gene delivery into human cells.
BioMacromolecules, 5: 327-338, 20014.
7.
Y. Wang, L. Wang, Z. Yin Y. Zhang, G.V. Aslanidi, A. Srivastava, C. Ling and C. Ling.
Pristimerin enhances recombinant adeno-associated virus serotype 2 vectormediated hepatocyte transgene expression both in vitro and in vivo. J. Integrative
Medicine, 12: 20-34, 2014.
8.
L.J. Tartaglia, A. Bennett, A.S. Plattner, C. Ling, N. Muzycka, C. Ling, A. Srivastava, and
M. Agbandje-McKenna, M. Molecular cloning, overexpression, and an efficient onestep purification of α5β1 integrin. Protein Expression and Purification, 92: 21-28, 2013.
9.
L. Song L, M.A. Kauss, M. Chandra, E. Kopin, G.R. Jayandharan, E. Miller, A.E. Rivers,
G.V. Aslanidi, C. Ling, B. Li, W. Ma, X. Li, L.M. Andino, L. Zhong, A.F. Tarantal,
M.C.Yoder, K.K. Wong, Jr., M. Tan, S. Chatterjee, and A. Srivastava. Optimizing the
transduction efficiency of capsid-modified AAV6 vectors in primary human
hematopoietic stem cells in vitro and in a xenograft mouse model in vivo.
Cytotherapy, 15: 986-998, 2013.
10.
L. Song, X. Li, G.R. Jayandharan, Y. Wang, G.V. Aslanidi, C. Ling, L. Zhong, G. Gao,
M.C. Yoder, C. Ling, M. Tan, and A. Srivastava. High-efficiency transduction of
primary human hematopoietic stem cells and erythroid lineage-restricted expression
by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo.
PLoS One, 8(3): e58757, 2013.
11.
G.V. Aslanidi, A.E. Rivers, L. Ortiz, C. L. Song, L. Govindasamy, M. Tan, M. AgbandjeMcKenna, and A. Srivastava. Optimization of recombinant AAV2 vectors for gene
therapy: The final threshold? PLoS One, 8(3): e59142, 2013.
12.
A.T. Martino, E. Basner-Tschakarjan, D.M. Markusic, J. Finn, C. Hinderer, S. Zhou, D.A.
Ostrov, A. Srivastava, H.C.J. Ertl, C. Terhorst, K.A. High, F. Mingozzi, and R.W. Herzog.
23
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by
capsid-specific CD8+ T cells. Blood, 121(12): 2224-33, 2013.
13.
Y. Wang, C. Ling, L. Song, L. Wang, G.V. Aslanidi, M. Tan, C. Ling, and A. Srivastava.
Limitations of encapsidation of recombinant AAV2 genomes in different serotype
capsids and their quantitation. Hum. Gene Therapy Methods, 23: 225-233, 2012.
14.
G.V. Aslanidi, A.E. Rivers, L. Ortiz, L. Govindasamy, C. Ling, G.R. Jayandharan, S.
Zolotukhin, M. Agbandje-McKenna, and A. Srivastava. High-efficiency transduction
of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2
vectors. Vaccine, 30: 3908-3917, 2012.
15.
J.H. Shin, Y. Yue, A. Srivastava, B. Smith, Y. Lai, and D. Duan. A simplified immune
suppression scheme leads to persistent micro-dystrophin expression in Duchenne
muscular dystrophy dogs. Hum. Gene Therapy, 23: 202-209, 2012.
16.
B. Cheng, C. Ling, Y. Dai, L.G. Glushakova, Y. Lu, S.W.Y. Gee, K.E. McGoogan, G.V.
Aslanidi, M. Park, P.W. Stacpoole, D. Siemann, C. Liu, A. Srivastava, and C. Ling.
Development of optimized AAV3 serotype vectors: Mechanism of high-efficiency
transduction of human liver cancer cells. Gene Therapy, 19: 375-384, 2012.
17.
J. Silver, M. Elder, T. Conlon, P. Cruz, A. Wright, A. Srivastava, and T.R. Flotte.
Recombinant AAV-mediated gene transfer for the potential therapy of adenosine
deaminase-deficient severe combined immune deficiency. Hum. Gene Therapy, 22:
935-949, 2011.
18.
K.A. Chen, P.E. Cruz, D.J. Lanuto, T.R. Flotte, D.R. Borchelt, A. Srivastava, J. Zhang, D.A.
Steindler, and T. Zheng. Cellular fusion for gene delivery to SCA1 affected Purkinje
neurons. Mol. Cell. Neurosci., 47: 61-70, 2011.
19.
G.R. Jayandharan, G.V. Aslanidi, A.T. Martino, S.C. Jahn, G.Q. Perrin, R.W. Herzog,
and A. Srivastava. Activation of the NF-B pathway by AAV vectors and its
implications in immune response and gene therapy. Proc. Natl. Acad. Sci., USA, 108:
3743-3748, 2011.
20.
W. Ma, B. Li, C. Ling, G.R. Jayandharan, A. Srivastava, and B.J. Byrne. A simple
method to achieve high-efficiency transduction by single-stranded AAV vectors in
vitro and in vivo. Hum. Gene Therapy, 22: 633-640, 2011.
21.
H. Petrs-Silva, A. Dinculescu, Q. Li, W. Deng, J.-J. Pang, S.-H. Min, V. Chiodo, A.W.
Neely, L. Govindasamy, A. Bennett, M. Agbandje-McKenna, L. Zhong, B. Li, G.R.
Jayandharan, A. Srivastava, A.S. Lewin, and W.W. Hauswirth. Novel properties of
tyrosine-mutant AAV2 vectors in the mouse retina. Mol. Therapy, 19: 293-301, 2011.
22.
Ling, Y. Lu, B. Cheng, K.E. McGoogan, S.W.Y. Gee, W. Ma, B. Li, G.V. Aslanidi, and A.
Srivastava. High-efficiency transduction of liver cancer cells by recombinant adenoassociated virus serotype 3 vectors. J. Vis. Exp., 49. Pii: 2538, doi: 10.3791/2538, 2011.
23.
C. Ling, Y. Lu, J. Kalsi, G.R. Jayandharan, B. Li, W. Ma, B. Cheng, S. Gee, K.
McGoogan, L. Zhong, L. Govindasamy, M. Agbandje-McKenna, and A. Srivastava.
Hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated
virus 3. Hum. Gene Therapy, 21: 1741-1747, 2010.
24
24.
M. Li, G.R. Jayandharan, B. Li, W. Ma, C. Ling, A. Srivastava, and L. Zhong. Highefficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant
AAV2 vectors for their potential use in cellular therapy. Hum. Gene Therapy, 21: 15271543, 2010.
25.
C. Qiao, W. Zhang, Z. Yuan, J.-H. Shin, G.R. Jayandharan, L. Zhong, A. Srivastava, X.
Xiao, and D. Duan. AAV6 capsid tyrosine to phenylalanine mutations improve gene
transfer to skeletal muscle. Hum. Gene Therapy, 21: 1343-1348, 2010.
26.
M.A. Kauss, L.J. Smith, L. Zhong, A. Srivastava, K.K. Wong, Jr., and S. Chatterjee.
Enhanced long-term transduction and multilineage engraftment of human
hematopoietic stem cells transduced with tyrosine-modified recombinant adenoassociated virus serotype 2. Hum. Gene Therapy, 21: 1129-1136, 2010.
27.
G.R. Jayandharan, L. Zhong, B.K. Sack, A.E. Rivers, M. Li, B. Li, R.W. Herzog, and A.
Srivastava. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper
viruses for efficient liver transduction by single-stranded AAV vectors: Therapeutic
expression of Factor IX at reduced vector doses. Hum. Gene Therapy, 21: 271-283,
2010.
28.
D. Markusic, R.W. Herzog, G. Aslanidi, B. Hoffman, B. Li, M. Li, G.R. Jayandharan, C.
Ling, I. Zolotukhin, W. Ma, S. Zolotukhin, A. Srivastava, and L. Zhong. High-efficiency
transduction and correction of murine hemophilia B using AAV2 vectors devoid of
multiple surface-exposed tyrosines. Mol. Therapy, 18: 2048-2056, 2010.
29.
C. Ojano-Dirain, L.G. Glushakova, L. Zhong, S. Zolotukhin, N. Muzyczka, A. Srivastava,
and P.W. Stacpoole. AAV8-siRNA vector-mediated knockdown of pyruvate
-mutant vectors in developing an
animal model of PDH deficiency. Mol. Genet. Metabol., 101: 183-191, 2010.
30.
H. Petrs-Silva, A. Dinculescu, Q. Li, S.H. Min, V. Chiodo, J. Pang, L. Zhong, S. Zolotukhin,
A. Srivastava, A.S. Lewin, and W.W. Hauswirth. High-efficiency transduction of the
mouse retina by tyrosine-mutant AAV serotype vectors. Mol. Therapy, 17: 463-471,
2009.
31.
I-J. Lin, Z. Zhou, V.J. Crusselle-Davis, B. Moghimi, K. Gandhi, A. Anantharaman, D.
Pantic, S. Huang, G.R. Jayandharan, L. Zhong, A. Srivastava, and J. Bungert.
Calpeptin increases the activity of USF and induces high-level globin gene expression
in erythroid cells. J. Biol. Chem., 284: 20130-20135, 2009.
32.
L.G. Glushakova, M.J. Lisankie, E.B. Eruslanov, C. Ojano-Dirain, I. Zolotukhin, L. Zhong,
C. Liu, A. Srivastava, and P.W. Stacpoole. AAV3-mediated transfer and expression of
the pyruvate dehydrogenase E1 subunit gene causes metabolic remodeling and
apoptosis in human liver cancer cells. Mol. Genet. Metabol., 98: 289-299, 2009.
33.
Z. Han, L. Zhong, A. Srivastava, and P.W. Stacpoole. Pyruvate dehydrogenase
complex deficiency due to ubiquitination and proteasome-mediated degradation
of the E1 subunit. J. Biol. Chem., 283: 237-243, 2008.
34.
L. Zhong, X. Zhou, Y. Li, K. Qing, X. Xiao, R.J. Samulski, and A. Srivastava. Single-polarity
recombinant adeno-associated virus 2 vector-mediated transgene expression in
25
vitro and in vivo: Mechanism of transduction. Mol. Therapy, 16: 290-295, 2008.
35.
Z. Han, K.M. Berendzen, L. Zhong, A. Srivastava, and P.W. Stacpoole. Optimization
and delivery of the pyruvate dehydrogenase E1a gene in primary human fibroblasts
by self-complementary recombinant AAV serotype vectors. Mol. Genet. Metabol.,
93: 381-387, 2008.
36.
Z. Han, L. Zhong, N. Maina, Z. Hu, X. Li, N.C. Chouthai, Bischof, K.A. Weigel-Van Aken,
W.B. Slayton, M.C. Yoder,, and A. Srivastava. Recombinant AAV proviral genomes
are stably integrated in primary murine hematopoietic stem cells. Hum. Gene
Therapy, 19: 267-278, 2008.
37.
N. Maina, L. Zhong, X. Li, W. Zhao, Z. Han, D. Bischof, G. Aslanidi, S. Zolotukhin, K.
Weigel-Van Aken, A.E. Rivers, W.B. Slayton, M.C. Yoder, and A. Srivastava.
Optimization of recombinant adeno-associated virus serotype vectors for human globin gene transfer and transgene expression. Hum. Gene Therapy, 19: 365-375,
2008.
38.
N. Maina, Z. Han, W. Zhao, X. Li, Z. Hu, L. Zhong, D. Bischof, K.A. Weigel-Van Aken,
W.B. Slayton, M.C. Yoder, and A. Srivastava. Recombinant scAAV serotype vectormediated transduction of hematopoietic stem cells and lineage-restricted long-term
transgene expression in progenitor cells in a murine serial bone marrow
transplantation model. Hum. Human Gene Therapy, 19: 376-383, 2008.
39.
G.R. Jayandharan, L. Zhong, B. Li, B. Kachniarz, and A. Srivastava. Strategies for
improving the transduction efficiency of single-stranded adeno-associated virus
vectors in vitro and in vivo. Gene Therapy, 15: 1287-1293, 2008.
40.
L. Zhong, B. Li, GR. Jayandharan, C.S. Mah, L. Govindasamy, M. Agbandje-McKenna,
R.W. Herzog, K.A. Weigel-Van Aken, J.A. Hobbs, S. Zolotukhin, N. Muzyczka, and A.
Srivastava. Tyrosine-phosphorylation of AAV2 vectors and its consequences on
intracellular trafficking and transgene expression. Virology, 381: 194-202, 2008.
41.
L. Zhong, B. Li, C.S. Mah, L. Govindasamy, M. Agbandje-McKenna, M.A. Cooper, R.W.
Herzog, I. Zolotukhin, K.H. Warrington, Jr., K.A. Weigel-Van Aken, J.A. Hobbs, S.
Zolotukhin, N. Muzyczka, and A. Srivastava. Next generation of adeno-associated
virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at
reduced doses. Proc. Natl. Acad. Sci., USA, 105: 7827-7832, 2008.
42.
W. Zhao, J. Wu, L. Zhong, and A. Srivastava. Adeno-associated virus 2-mediated
gene transfer: Identification of a cellular serine/threonine protein phosphatase
involved in augmenting vector transduction efficiency. Gene Therapy, 14: 545-550,
2007.
43.
J. Wu, W. Zhao, L. Zhong, B. Li, W. Ma, K.A. Weigel-Kelley, K.H. Warrington. Jr., and A.
Srivastava. Self-complementary recombinant adeno-associated virus vectors:
Packaging capacity and the role of Rep proteins in vector purity. Hum. Gene
Therapy, 18: 171-182, 2007.
44.
Z. Han, M. Gorbatyuk, J. Thomas Jr, K.M. Berendzen, A.S. Lewin, A. Srivastava, and
P.W. Stacpoole. Down-regulation of rat pyruvate dehydrogenase E1 mRNA gene
expression by self-complementary AAV-mediated small interfering RNA delivery.
26
Mitochondrion, 7: 253-259, 2007.
45.
L. Zhong, W. Zhao, J. Wu, B. Li, B. Li, S. Zolotukhin, L. Govindasamy, M. AgbandgeMcKenna, and A. Srivastava. A dual role of EGFR protein tyrosine kinase signaling in
ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol. Therapy,
15: 1323-1330, 2007.
46.
L. Zhong, W. Li, Y. Li, W. Zhao, J. Wu, B. Li, N. Maina, D. Bischof, K. Qing, K.A. WeigelKelley, I. Zolotukhin, K. Warrington, X. Li, W.B. Slayton, M.C. Yoder, and A. Srivastava.
Evaluation of primitive murine hematopoietic stem and progenitor cell transduction
in vitro and in vivo by recombinant adeno-associated virus vector serotypes 1
through 5. Hum. Gene Therapy, 17: 321-333, 2006.
47.
W. Zhao, L. Zhong, J. Wu, L. Chen, K. Qing, K.A. Weigel-Kelley, S.H. Larsen, W. Shou,
K.H. Warrington, Jr., and A. Srivastava. Role of cellular FKBP52 protein in intracellular
trafficking of recombinant adeno-associated virus 2 vectors. Virology, 353: 283-293,
2006.
48.
K.A. Weigel-Kelley, L. Chen, M.C. Yoder, and A. Srivastava. Role of integrin cross-talk
in the tropism of human parvovirus B19. Hum. Gene Therapy, 17: 909-920, 2006.
49.
Z. Yang, I.M. Wolf, H. Chen, S. Periyasamy, Z. Chen, W. Yong, S. Shi, W. Zhao, J. Xu, A.
Srivastava, E.R. Sanchez, and W. Shou. FKBP52 is essential to uterine reproductive
physiology controlled by the progesterone receptor A isoform. Mol. Endocrinol., 20:
2682-2694, 2006.
50.
L. Zhong, K.Y. Qing, Y. Si, L. Chen, M.Q. Tan and A. Srivastava. Heat-shock treatmentmediated increase in transduction by adeno-associated virus 2-vectors is
independent of the cellular heat-shock protein 90. J. Biol. Chem., 279: 12714-12723,
2004.
51.
L. Zhong, W. Li, Z, Yang, L.Y. Chen, Y. Li, K.Y. Qing, K.A. Weigel-Kelley, M.C. Yoder, W.
Shou and A. Srivastava. Improved transduction of primary murine hepatocytes by
recombinant adeno-associated virus 2 vectors in vivo. Gene Therapy, 11: 1165-1169,
2004.
52.
L. Zhong, L.Y. Chen, Y. Li, K.Y. Qing, K.A. Weigel-Kelley, R.J. Chan, M.C. Yoder, and A.
Srivastava. Self-complementary adeno-associated virus 2 (AAV)-T cell protein
tyrosine phosphatase vectors as helper-viruses to improve transduction efficiency of
conventional single-stranded AAV vectors in vitro and in vivo. Mol. Therapy, 10: 950957, 2004.
53.
L. Zhong L, W. Li, Z. Yang, K. Qing, M. Tan, J. Hansen, Y. Li, L. Chen, R.J. Chan, D.
Bischof, N. Maina, K.A. Weigel-Kelley, W. Zhao, S.H. Larsen, M.C. Yoder, W. Shou, and
A. Srivastava. Impaired intracellular trafficking and uncoating of recombinant
adeno-associated virus 2 vectors limit efficient transduction of primary murine
hematopoietic cells. Hum. Gene Therapy, 15: 1207-1218, 2004.
54.
K.Y. Qing, W. Li, L. Zhong, M.Q. Tan, J. Hansen, K.A. Weigel-Kelley, L. Chen, M.C. Yoder
and A. Srivastava. Adeno-associated virus 2-mediated gene transfer: Role of T-cell
protein tyrosine phosphatase in transgene expression in established cell lines in vitro
and transgenic mice in vivo. J. Virol., 77: 2741-2746, 2003.
27
55.
K.A. Weigel-Kelley, M.C. Yoder and A. Srivastava. 51 integrin as a cellular coreceptor for human parvovirus B19: Requirement of 1 integrin activation for viral
entry. Blood, 102: 3927-3933, 2003.
56.
J. Hansen, K.Y. Qing and A. Srivastava. Adeno-associated virus 2-mediated gene
transfer: Altered endocytic processing enhances transduction efficiency in murine
fibroblasts. J. Virol., 75: 4080-4090, 2001.
57.
K.A. Weigel-Kelley, M.C. Yoder and A. Srivastava. Recombinant human parvovirus
B19 vectors: Erythrocyte P antigen is necessary but not sufficient for successful
transduction of human hematopoietic cells. J. Virol., 75: 4110-4116, 2001.
58.
M.Q. Tan, K.Y. Qing, S.Z. Zhou, M.C. Yoder and A. Srivastava. Adeno-associated virus
2-mediated transduction and erythroid lineage-restricted, long-term expression of
the normal human b-globin gene in hematopoietic cells from homozygous thalassemic mice. Mol. Therapy, 3: 940-946, 2001.
59.
K.Y. Qing, J. Hansen, K.A. Weigel-Kelley, M.Q. Tan, S.Z. Zhou and A. Srivastava.
Adeno-associated virus 2-mediated gene transfer: Role of cellular FKBP52 protein in
transgene expression. J. Virol., 75: 8968-8976, 2001.
60.
J. Hansen, K.Y. Qing and A. Srivastava. Infection of purified nuclei by adenoassociated virus 2. Mol. Therapy, 3: 289-296, 2001.
61.
J. Hansen, K.Y. Qing, H.-J. Kwon, C. Mah and A. Srivastava. Impaired intracellular
trafficking of adeno-associated virus 2 vectors limits efficient transduction of murine
fibroblasts. J. Virol., 74: 992-996, 2000.
62.
K.Y. Qing, C. Mah, J. Hansen, S.Z. Zhou, V.J. Dwarki and A. Srivastava. Human
fibroblast growth factor receptor 1 is a co-receptor for infection by adenoassociated virus 2. Nature Med., 5: 71-77, 1999.
63.
C. Kurpad, P. Mukherjee, X.-S. Wang, S. Ponnazhagan, L. Li, M.C. Yoder and A.
Srivastava. Adeno-associated virus 2-mediated transduction and erythroid lineagerestricted expression from parvovirus B19p6 promoter in primary human
hematopoietic progenitor cells. J. Hematother. Stem Cell Res., 8: 585-592, 1999.
64.
K.Y. Qing, B. Khuntirat, C. Mah, D.M. Kube, X.-S. Wang, S. Ponnazhagan, S.Z. Zhou,
V.J. Dwarki, M.C. Yoder and A. Srivastava. Adeno-associated virus type 2-mediated
gene transfer: Correlation of tyrosine phosphorylation of the cellular single-stranded
D sequence-binding protein with transgene expression in human cells in vitro and
murine tissues in vivo. J. Virol., 72: 1593-1599, 1998.
65.
X.-S. Wang and A. Srivastava. Rescue and autonomous replication of the adenoassociated virus type 2 genomes containing Rep-binding site mutations in the viral
p5 promoter. J. Virol., 72: 4811-4818, 1998.
66.
S. Ponnazhagan, K.A. Weigel, S.P. Raikwar, P. Mukherjee, M.C. Yoder and A.
Srivastava. Recombinant human parvovirus B19 vectors: Erythroid cell-specific
delivery and expression of transduced genes. J. Virol., 72: 5224-5230, 1998.
28
67.
X.-S. Wang, B. Khuntirat, K.Y. Qing, S. Ponnazhagan, D.M. Kube, S.Z. Zhou, V.J. Dwarki
and A. Srivastava. Characterization of wild-type adeno-associated virus type 2-like
particles generated during recombinant viral vector production and strategies for
their elimination. J. Virol., 72: 5472-5480, 1998.
68.
R.M. Jindal, R.A. Sidner, M.R. Bochan, and A. Srivastava. Adeno-associated virus
vectors: Potential for gene therapy. Graft, 1: 146-152, 1998.
69.
C. Mah, K.Y. Qing, B. Khuntirat, S. Ponnazhagan, X.-S. Wang, D.M. Kube, M.C. Yoder
and A. Srivastava. Adeno-associated virus 2-mediated gene transfer: Role of
epidermal growth factor receptor protein tyrosine kinase in transgene expression. J.
Virol., 72: 9835-9843, 1998.
70.
S. Ponnazhagan, D. Erikson, W.G. Kearns, S.Z. Zhou, P. Nahreini, X-S. Wang and A.
Srivastava. Lack of site-specific integration of the recombinant adeno-associated
virus 2 genomes in human cells. Hum. Gene Therapy, 8: 275-284, 1997.
71.
X.-S. Wang and A. Srivastava. A novel terminal resolution-like site in the adenoassociated virus type 2 genome. J. Virol., 71: 1140-1146, 1997.
72.
S. Ponnazhagan, P. Mukherjee, M.C. Yoder, X.-S. Wang, S.Z. Zhou, J. Kaplan, S.
Wadsworth and A. Srivastava. Adeno-associated virus 2-mediated gene transfer in
vivo: Organ-tropism and expression of transduced sequences in mice. Gene, 190:
203-210, 1997.
73.
X.-S. Wang, K.Y. Qing, S. Ponnazhagan and A. Srivastava. Adeno-associated virus 2
DNA replication in vivo: Mutation analyses of the D-sequence in viral inverted
terminal repeats. J. Virol., 71: 3077-3082, 1997.
S. Ponnazhagan, M.C. Yoder and A. Srivastava. Adeno-associated virus type 2mediated transduction of murine hematopoietic cells with long-term repopulating
ability and sustained expression of a human globin gene in vivo. J. Virol., 71: 30983104, 1997.
74.
75.
K. Qing, T. Bachelot, P. Mukherjee, X.-S. Wang, L. Peng, M.C. Yoder, P. Leboulch and
A. Srivastava. Adeno-associated virus type 2-mediated transfer of ecotropic
retrovirus receptor cDNA allows retroviral transduction of established and primary
human cells. J. Virol., 71: 5663-5667, 1997.
76.
D.M. Kube and A. Srivastava. Quantitative DNA slot blot analysis: Inhibition of DNA
binding to membranes by magnesium ions. Nucl. Acids Res., 25: 3375-3376, 1997.
77.
D.M. Kube, S. Ponnazhagan and A. Srivastava. Encapsidation of adeno-associated
virus type 2 Rep proteins in wild-type and recombinant progeny virions: Repmediated growth inhibition of primary human cells. J. Virol., 71: 7361-7371, 1997.
78.
C.A. Grant, S. Ponnazhagan, X.-S. Wang, A. Srivastava and T. Li. Evaluation of
recombinant adeno-associated virus as a gene transfer vector for the retina. Curr.
Eye Res., 16: 949-956, 1997.
79.
S. Ponnazhagan, P. Mukherjee, X.-S. Wang, K.Y. Qing, D.M. Kube, C. Mah, C. Kurpad,
M.C. Yoder, E.F. Srour and A. Srivastava. Adeno-associated virus type 2-mediated
transduction of primary human bone marrow-derived CD34+ hematopoietic
29
progenitor cells: Donor variation and correlation of transgene expression with cellular
differentiation. J. Virol., 71: 8262-8267, 1997.
80.
K.Y. Qing, X.-S. Wang, D.M. Kube, S. Ponnazhagan, A. Bajpai and A. Srivastava. Role
of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2mediated transgene expression. Proc. Natl. Acad. Sci., USA, 94: 10879-10884, 1997.
81.
S.Z. Zhou, Q. Li, G. Stamatoyannopoulos and A. Srivastava. Adeno-associated virus
2-mediated transduction and erythroid cell-specific expression of a human -globin
gene. Gene Therapy, 3: 223-229, 1996.
82.
X.-S. Wang, S. Ponnazhagan and A. Srivastava. Rescue and replication of adenoassociated virus type 2 as well as vector DNA sequences from recombinant plasmids
containing deletions in viral inverted terminal repeats: Selective encapsidation of
viral genomes in progeny virions. J. Virol., 70: 1668-1677, 1996.
83.
S. Ponnazhagan, X.-S. Wang, M.J. Woody, F. Luo, L.Y. Kang, M.L. Nallari, N.C. Munshi,
S.Z. Zhou and A. Srivastava. Differential expression from p6 promoter of parvovirus
B19 in human cells following plasmid transfection and recombinant adenoassociated virus 2 (AAV) infection: Human megakaryocytic leukaemia cells are nonpermissive for AAV infection. J. Gen. Virol., 77: 1111-1122, 1996.
84.
X.-L. Sun, B.R. Murphy, S. Gulapalli, J. Mackins, H.N. Jayaram. A. Srivastava and A.C.
Antony. Transduction of folate receptor cDNA into cervical carcinoma cells using
recombinant adeno-associated virions delays cell proliferation in vitro and in vivo. J.
Clin. Invest., 96: 1535-1547, 1995.
85.
F. Luo, S.Z. Zhou, S. Cooper, N.C. Munshi, H.S. Boswell, H.E. Broxmeyer and A.
Srivastava.
Adeno-associated virus 2-mediated transduction and functional
expression of a gene encoding the human granulocyte-macrophage colonystimulating factor. Exp. Hematol., 23: 1261-1267, 1995.
86.
X.-S. Wang, S. Ponnazhagan and A. Srivastava. Rescue and replication signals of the
adeno-associated virus 2 genome. J. Mol. Biol., 250: 573-580, 1995.
87.
X.-S. Wang, M.C. Yoder, S.Z. Zhou and A. Srivastava. Parvovirus B19 promoter at map
unit 6 confers autonomous replication competence and erythroid specificity to
adeno-associated virus 2 in primary human hematopoietic progenitor cells. Proc.
Natl. Acad. Sci., USA, 92: 12416-12420, 1995.
88.
S. Ponnazhagan, M.J. Woody, X.-S. Wang, S.Z. Zhou and A. Srivastava. Transcriptional
transactivation of parvovirus B19 promoters in non-permissive human cells by
adenovirus type 2. J. Virol., 69: 8096-8101, 1995.
89.
T. Szekeres, K. Gharehbaghi, M. Fritzer, M.J. Woody, A. Srivastava, B. van't Riet, H.N.
Jayaram and H.L. Elford. Biochemical and antitumor activity of trimidox, a new
inhibitor of ribonucleotide reductase. Cancer Chemother. Pharmacol., 34: 63-66,
1994.
90.
S. Ponnazhagan, M.L. Nallari and A. Srivastava. Suppression of human -globin gene
expression mediated by the recombinant adeno-associated virus 2-based anti-sense
vectors. J. Exp. Med., 179: 733-738, 1994.
30
91.
S.Z. Zhou, S. Cooper, L.Y. Kang, L. Ruggieri, S. Heimfeld, A. Srivastava and H.E.
Broxmeyer. Adeno-associated virus 2-mediated high-efficiency gene transfer into
immature and mature subsets of hematopoietic progenitor cells in human umbilical
cord blood. J. Exp. Med., 179: 1867-1875, 1994.
92.
J. Borrow, J. Shipley. K. Howe, F. Kiley, A. Goddard, D. Sheer, A. Srivastava, A. Antony,
T. Fioretos, F. Mitelman and E. Solomon. Molecular analysis of simple variant
translocations in acute promyelocytic leukemia. Genes, Chrom. Cancer, 9: 234-243,
1994.
93.
N.C. Munshi, S.Z. Zhou, M.J. Woody, D.A. Morgan and A. Srivastava. Successful
replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02.
J. Virol., 67: 562-566, 1993.
94.
P. Nahreini, M.J. Woody S.Z. Zhou and A. Srivastava. Versatile adeno-associated virus
2-based vectors for constructing recombinant virions. Gene, 124: 257-262, 1993.
95.
S.Z. Zhou, H.E. Broxmeyer, S. Cooper, M.A. Harrington and A. Srivastava. Adenoassociated virus 2-mediated gene transfer in murine hematopoietic progenitor cells.
Exp. Hematol., 21: 928-933, 1993.
96.
P. Nahreini and A. Srivastava. Rescue of the adeno-associated virus 2 genome
correlates with alterations in DNA-modifying enzymes in human cells. Intervirology,
33: 109-115, 1992.
97.
P. Nahreini, S.H. Larsen and A. Srivastava. Cloning and integration of DNA fragments
in human cells via the inverted terminal repeats of the adeno-associated virus 2
genome. Gene, 119: 265-272, 1992.
98.
C.H. Srivastava, S.Z. Zhou, N.C. Munshi and A. Srivastava. Parvovirus B19 replication
in human umbilical cord blood cells. Virology, 189: 456-461, 1992.
99.
A. Srivastava, R.J. Shmookler Reis and S. Goldstein. Absence of reverse transcriptase
activity in normal human diploid fibroblasts. Mech. Ageing Dev., 51: 133-138, 1990.
100.
H.S. Boswell, T.S. Nahreini, G.S. Burgess, A. Srivastava, L.M. Helvering, T.G. Gabig, L.
Inhorn, E.F. Srour and M. Harrington. A RAS oncogene imparts growth factorindependence to myeloid cells that abnormally regulate protein kinase C: A nonautocrine transformation pathway. Exp. Hematol., 18: 452-460, 1990.
101.
A. Srivastava, E. Bruno, R. Briddell, R. Cooper, C. Srivastava, K. van Besien and R.
Hoffman. Parvovirus B19-induced perturbation of human megakaryocyto-poiesis in
vitro. Blood, 76: 1997-2004, 1990.
102.
M.A. Dayton, P. Nahreini and A. Srivastava. Augmented nuclease activity during
cellular senescence in vitro. J. Cell. Biochem., 39: 75-85, 1989.
103.
P. Nahreini and A. Srivastava. Rescue and replication of the adeno-associated virus
genome in mortal and immortal human cells. Intervirology, 30: 74-85, 1989.
104.
H. Ashktorab and A. Srivastava.
Identification of nuclear proteins that specifically
31
interact with the adeno-associated virus type 2 inverted terminal repeat hairpin DNA.
J. Virol., 63: 3034-3039, 1989.
105.
C.H. Srivastava, R.J. Samulski, L. Lu, S.H. Larsen and A. Srivastava. Construction of a
recombinant human parvovirus B19: Adeno-associated virus 2 DNA inverted terminal
repeats are functional in an AAV-B19 hybrid virus. Proc. Natl. Acad. Sci., USA, 86:
8078-8082, 1989.
106.
A. Srivastava, H.S. Boswell, N. Heerema, P. Nahreini, R.C. Lauer, A. C. Antony, R.
Hoffman and G. Tricot. KRAS2 oncogene over-expression in a patient with a
myelodysplastic syndrome involving translocation of chromosome 5q. Cancer
Genet. Cytogenet., 35: 61-71, 1988.
107.
A. Srivastava and L. Lu. Replication of the B19 parvovirus in highly enriched
hematopoietic progenitor cells from normal human bone marrow. J. Virol., 62: 30593063, 1988.
108.
A. Srivastava, N.A. Heerema, R.C. Lauer, P. Nahreini, H.S. Boswell, R. Hoffman and
A.C. Antony. A variant t (X;15) (p11;q22) in acute promyelocytic leukemia. Cancer
Genet. Cytogenet., 29: 65-74, 1987.
109.
H.S. Boswell, A. Srivastava, J.S. Burgess, P. Nahreini, N.A. Heerema, L. Inhorn, F.
Padgett, E. B. Walker and R.W. Geib. Cellular control of in vitro progression of murine
myeloid leukemia: Transformation accompanies acquisition of growth factor-and
stromal-cell independence. Leukemia, 1: 765-771, 1987.
110.
A. Srivastava. Replication of the adeno-associated virus DNA termini in vitro.
Intervirology, 27: 138-147, 1987.
111.
A. Srivastava, J.S. Norris, R.J. Shmookler Reis and S. Goldstein. c-Ha-ras-1 protooncogene amplification and over-expression during the limited replicative lifespan
of normal human fibroblasts. J. Biol. Chem., 260: 6404-6409, 1985.
112.
R.J. Shmookler Reis, A. Srivastava, D.T. Beranek and S. Goldstein. The human alphoid
family of tandemly repeated DNA: Sequence of cloned tetrameric fragments and
analysis of familial divergence. J. Mol. Biol., 186: 31-41, 1985.
113.
J.S. Norris, L.E. Cornett, J.W. Hardin, P.O. Kohler, S.L. MacLeod, A. Srivastava, A.J. Syms
and R.G. Smith. Autocrine regulation of growth: Glucocorticoids inhibit transcription
of c-sis oncogene specific RNA transcripts. Biochem. Biophys. Res. Commun., 122:
124-128, 1984.
114.
R.J. Samulski, A. Srivastava, K.I. Berns and N. Muzyczka. Rescue of adeno-associated
virus from recombinant plasmids: Gene correction within the terminal repeats of
AAV. Cell, 33: 135-143, 1983.
115.
A. Srivastava, E.W. Lusby and K.I. Berns. Nucleotide sequence and organization of
the adeno-associated virus 2 genome. J. Virol., 45: 555-564, 1983.
116.
A. Srivastava and M.J. Modak. Phenylglyoxal as a template site-specific reagent for
DNA and RNA polymerases. J. Biol. Chem., 255: 917-921, 1980.
32
117.
M.J. Modak, A. Srivastava and E. Gillerman. Observations on the phosphonoformic
acid inhibition of RNA dependent DNA polymerases. Biochem. Biophys. Res.
Commun., 96: 931-938, 1980.
118.
A. Srivastava and M.J. Modak. Enzyme activities associated with avian and murine
retroviral DNA polymerases: Catalysis of and active site involvement in
pyrophosphate exchange and pyrophosphorolysis reactions. J. Biol. Chem., 255:
2000-2004, 1980.
119.
A. Srivastava and M.J. Modak. Biochemistry of terminal deoxynucleotidyl transferase:
Identification, characterization, requirements and active-site involvement in the
catalysis of associated pyrophosphate exchange and pyrophosphorolysis activities.
Biochemistry, 19: 3270-3275, 1980.
120.
M.J. Modak and A. Srivastava. Reverse transcriptase-associated RNaseH does not
require zinc for catalysis. J. Biol. Chem., 254: 4756-4759, 1979.
121.
A. Srivastava and M.J. Modak. Reverse transcriptase-associated RNaseH: IV.
Pyrophosphate does not inhibit the RNaseH activity of AMV DNA polymerase.
Biochem. Biophys. Res. Commun., 91: 892-899, 1979.
122.
A. Srivastava, A. Antony and T. Ramakrishnan. Molecular mechanism for the specific
inhibition of reverse transcriptase of Rous sarcoma virus by the copper complexes of
isonicotinic acid hydrazide. Biochem. Pharmacol., 27: 579-584, 1978.
123.
A. Srivastava, A. Antony, T. Ramakrishnan and U.S. Nandi. Studies on the copper
complex of isonicotinic acid hydrazide - A new antiviral drug. Curr. Sci., 46: 69-71,
1977.
Manuscripts in Submission/Preparation:
1.
Y. Wang, L. Wang, Y. Lu, J.-H. Kim, G.V. Aslanidi, A. Srivastava, C. Ling, and C. Ling.
Functional role of the adeno-associated virus 2 inverted terminal repeat in
messenger RNA transport and transgene expression. Submitted to J. Gen. Virology,
2015.
2.
S. Hareendran, N. Gabriel, B. Ramakrishna, A. Srivastava, A. Srivastava, and G.R.
Jayandharan. Regulation of AAV-mediated transgene expression by a host cell stress
response protein, PARP-1. To be submitted to J. Gene Medicine, 2015.
3.
Y. Lu, C. Ling, B. Cheng, G.R. Jayandharan, C. Ling, and A. Srivastava. Involvement
of glucocorticoid receptor signaling in AAV2 vector-mediated transgene expression.
To be submitted to the Proc. Natl. Acad. Sci., USA, 2015.
4.
C. Ling, G.R. Jayandharan, Y. Lu, G. Aslanidi, X, Xiao, R.J. Samulski, N. Muzyczka, and
A. Srivastava. Mechanism of encapsidation of recombinant AAV2 genomes into viral
capsids. To be submitted to J. Virology, 2015.
5.
B. Li, W. Ma, G.V. Aslanidi, C. Ling, K.V. Vliet, M. Agbandje-McKenna, and A.
Srivastava. Site-directed mutagenesis of surface-exposed lysine residues leads to
33
high-efficiency transduction by recombinant AAV2 and AAV8 vectors. To be
submitted to Hum Gene Therapy, 2015.
6.
L. Zhong, C. Ling, Y. Lu, S. Li, M. Li, Q. Su R. He, Y. Wang, Y. Zhang, K. Vercauteren, L.
Verhoye, G.V. Aslanidi, C. Ling, P. Meuleman, A. Srivastava, and G. Gao. Highefficiency gene transfer and transgene expression mediated by optimized
recombinant AAV3 vectors in primary human hepatocytes in vitro and in no-human
primate livers in vivo. To be submitted to Sci. Transl. Med., 2015.
Book Chapters:
1.
A.R. Rivers, and A. Srivastava. Gene therapy of hemoglobinopathies. In: A Guide to
Human Gene Therapy. (R.W. Herzog and S. Zolotukhin, eds.). World Scientific
Publishing, Hackensack, Ch 12, pp.197-212, 2010.
2.
L. Zhong, and A. Srivastava. Adeno-associated viral vectors. In: Encyclopedia of
the Human Genome, pp. 1-8, John Wiley & Sons, Ltd., London, 2007.
3.
A. Srivastava. Delivery of DNA to stem cells in vivo using AAV vectors. In: Gene
Delivery to Mammalian Cells: Methods in Molecular Biology (W.C. Heiser, ed.).
Humana Press, Totowa, Vol. 256, 245-254, 2003.
A. Srivastava. Parvovirus vectors for human gene therapy. In: Current Opinion in
Molecular Therapeutics (M.C. Dinauer and W. Gunzburg, eds.). PharmaPress,
London, 3: 491-496, 2001.
A. Srivastava. Gene transfer with adeno-associated virus vectors. Viral Vectors: Gene
Therapy and Basic Science (A. Cid-Arregui and A. Garcia-Carranca, eds.). Eaton
Publishing, 11-26, 2000.
A. Srivastava, C. Kurpad and M.C. Yoder. Erythroviruses as gene transfer vehicles. In:
Contributions to Microbiology (S. Faisst, and J. Rommelaere, eds.). Karger, Basel, Vol.
4: 133-148, 2000.
4.
5.
6.
7.
A. Srivastava. Parvovirus vectors for human hematopoietic gene therapy. In: Blood
Cell Biochemistry: Hematopoiesis and Gene Therapy (L.J. Fairbairn and N. Testa,
eds.). Kluwer Academic/Plenum Publishers, New York, 89-122, 1999.
8.
A. Srivastava. Delivery systems for gene therapy: Adeno-Associated Virus 2. In: Stem
Cell Biology and Gene Therapy (G. Stein, P. Quesenberry, B. Forget and S. Weissman,
eds.). Wiley-Liss, New York, 257-288, 1998.
9.
A. Srivastava, X.-S. Wang, S. Ponnazhagan, S.Z. Zhou and M.C. Yoder. Adenoassociated virus 2-mediated transduction and erythroid lineage-specific expression
in human hematopoietic progenitor cells. Curr. Top. Microbiol. Immunol., 218: 93117, 1996.
10.
H.E. Broxmeyer, S. Cooper, M. Etienne-Julan, X.-S. Wang, S. Ponnazhagan, S. Braun,
L. Lu, and A. Srivastava. Cord blood transplantation and the potential for gene
therapy: Gene transduction using a recombinant adeno-associated viral vector.
N.Y. Acad. Sci., 770: 105-115, 1995.
11.
H.E. Broxmeyer, S. Cooper, M. Etienne-Julan, S. Braun, L. Lu, S.D. Lyman and A.
34
Srivastava. Cord blood hematopoietic stem/progenitor cell growth and transduction
using adeno-associated and retroviral vectors: Ontogeny of hematopoiesis. In:
Foetal and Neonatal Hematopoiesis and Mechanisms of Bone Marrow Failure. John
Libbey Eurotext Ltd., Montrouge, Vol. 235, 109-114, 1995.
12.
H.E. Broxmeyer, L. Lu, J. Gaddy, L. Ruggieri, A. Srivastava and G. Risdon. Human
umbilical cord blood transplantation: Expansion and gene therapy of hematopoietic
stem and progenitor cells and immunology. In: Hematopoietic Stem Cells and
Therapeutic Applications (D.J. Levitt, ed.). pp. 297-317, 1995.
13.
A. Srivastava. Parvovirus-based vectors for human gene therapy. Blood Cells, 20:
531- 538, 1994.
14.
G.J. Tricot, M.T. Rizzo and A. Srivastava. Transformation of MDS to leukemia. In: The
myelodysplastic syndromes (G.J. Mufti and D.A. Galton, eds.). p.89-95, Churchill
Livingstone, Edinburgh, 1992.
15.
P. Nahreini and A. Srivastava. Replication of adenovirus 2 and adeno-associated
virus 2 in young and senescent human diploid fibroblasts. In: Biomedical Advances
in Aging (A.L. Goldstein, ed.). p. 89-107, Plenum Press, New York, 1990.
16.
S. Goldstein, A. Srivastava, K.T. Riabowol and R.J. Shmookler Reis. Changes in genetic
organization and expression in aging cells. In: Molecular Basis of Aging, Brookhaven
Symposium in Biology. Plenum Publishing Corp., New York, 1985.
17.
S. Goldstein, A. Srivastava, K. T. Riabowol and R.J. Shmookler Reis. Alternations in
genetic organization and expression in aging human fibroblasts. In: Cellular and
Molecular Aspects of Aging: The Red Cell as a Model, pp. 255-267. Alan R. Liss, New
York, 1985.
18.
R.J. Shmookler Reis, A. Srivastava, J.W. Hardin, K.T. Riabowol and S. Goldstein. Clonal
diversification of DNA structure and transcription during cellular senescence. In:
Molecular Biology of Aging: Gene Stability and Gene Expression (R.S. Sohal, L.
Birnbaum and R.G. Cutler (eds.), pp. 37-48, Raven Press, New York, 1985.
19.
R.J. Shmookler Reis, A. Srivastava and S. Goldstein. Macromolecular correlates of
cellular senescence. In: Interrelationship among Aging, Cancer and Differentiation
(B. Pullman, ed.), D. Reidel Publishing Co., pp. 121-132, Holland, 1985.
20.
S. Goldstein, A. Srivastava, K.T. Riabowol and R.J. Shmookler Reis. Alterations of
genetic structure and expression in aging cells. In: NATO Conference on Aging,
Plenum Publishing Corporation, New York, 1984.
21.
S. Goldstein, A. Srivastava, K.T. Riabowol and R.J. Shmookler Reis. Altered genetic
organization and expression in aging human fibroblasts. In: Topics in Aging Research
in Europe, Vol. 3, 259-273, (A.L. de Weck, ed.), EURAGE, Rijswijk, The Netherlands, 1984
22.
N. Muzyczka, R.J. Samulski, P. Hermonat, A. Srivastava, and K.I. Berns. The genetics
of adeno-associated virus. Adv. Exptl. Med. Biol., 179: 151-61, 1984.
23.
K.I. Berns, R.J. Samulski, A. Srivastava, and N. Muzyczka. Symmetry and self-repair in
adeno-associated virus DNA replication. In: Mechanisms of DNA Replication and
35
Recombination. Vol. 10, 353-366, (N.R. Cozzarelli, ed.), Alan R. Liss, New York, 1983.
24.
T. Ramakrishnan, A. Antony, A. Srivastava, U.S. Nandi, J. Jackson and W.E. Levinson.
Effect of copper complex of isonicotinic acid hydrazide on Rous sarcoma virus and
other viruses. In: Molecular Basis of Host-Virus Interaction (M. Chakravorty, ed.).
Science Press, New Jersey, 1978.
25.
A. Srivastava, A. Antony, T. Ramakrishnan, U.S. Nandi and W.E. Levinson. Effect of
copper complexes of isonicotinic acid hydrazide on the nucleic acid replication of
Rous sarcoma virus. In: The Structure and Functional Aspects of Chromosomes, pp.
355-364, Bhabha Atomic Research Center, Bombay, 1975.
Reviews:
1.
L. Zhong, G.R. Jayandharan, G.V. Aslanidi, R.W. Herzog, and A. Srivastava. Novel
adeno-associated viral vectors and strategies for the potential gene therapy of
hemophilia. J. Genet. Syndromes and Gene Therapy, doi: 10.4172/2157-7412.S1-008,
2012.
2.
G.R. Jayandharan, A. Srivastava, and A. Srivastava. Role of molecular genetics in
haemophilia: From diagnosis to therapy. Seminars in Thrombosis and Hemostasis. 38:
64-78, 2012.
3.
G.L. Rogers, A.T. Martino, G.V. Aslanidi, G.R. Jayandharan, A. Srivastava, and R.W.
Herzog. Innate immune responses to AAV vectors. Frontiers in Microbial Immunology,
2: 194-203, 2011.
4.
R.W. Herzog, O. Cao, and A. Srivastava. Two Decades of Clinical Gene Therapy –
Success is Finally Mounting. Disc. Med., 9: 105-111, 2010.
5.
A. Srivastava. Adeno-associated virus-mediated gene transfer. J. Cell. Biochem., 105:
17-24, 2008.
6.
L. Zhong, W. Zhao, J. Wu, N. Maina, Z. Han, and A. Srivastava. Gene transfer in
hematopoietic stem and progenitor as an analytical tool and a therapeutic tool.
Curr. Gene Therapy, 6: 683-698, 2006.
7.
A. Srivastava. Hematopoietic stem cell transduction by recombinant adenoassociated virus vectors: Problems and solutions. Hum. Gene Therapy, 16: 792-798,
2005.
8.
A. Srivastava. Obstacles to human hematopoietic stem cell transduction by
recombinant adeno-associated virus 2 vectors. J. Cell. Biochem., 38: 39-45, 2002.
9.
K.A. Weigel-Kelley and A. Srivastava. Recombinant human parvovirus B19 vectors.
Pathol. Biol., 50: 295-306, 2002.
10.
C. Mah, K.Y. Qing, J. Hansen, B. Khuntirat, M.C. Yoder and A. Srivastava. Gene
transfer with adeno-associated virus vectors: The growth factor receptor connection.
Gene Therap. Mol. Biol., 3: 57-65, 1999.
36
Miscellaneous:
1.
D. Sarkar, G.Q. Perrin, S. Zolotukhin, A. Srivastava, and R.W. Herzog. Gene therapists
determined to stop the bleeding! J. Genet. Syndromes and Gene Therapy, doi:
10.4172/2157-7412.S1-e001, 2012.
2.
A. Srivastava. Big breakthroughs with small viruses. Internatl. Innovation, 48-50, 2010.
3.
A. Srivastava. Antiviral activity of copper complexes of isoniazid against RNA tumor
viruses. Resonance, 14: 754-760, 2009.
4.
A.P. Varki, L.G. Baum, S.L. Bellis, R.D. Cummings, J.D. Esko, G.W. Hart, R.J. Linhardt, J.B.
Lowe, R.P. McEver, A. Srivastava, and R. Sarkar. Working Group Report: The roles of
glycans in hemostasis, inflammation and vascular biology. Glycobiology, 18: 747-749,
2008.
5.
K.Y. Qing, J. Hansen and A. Srivastava. Adeno-associated virus 2 co-receptors?
Nature Med., 5: 468, 1999.
6.
A. Srivastava. Gene therapy with viral vectors: The hope, the problems, and the
solution. J. Hematother. Stem Cell Res., 10: 321-322, 2001.
7.
A. Srivastava. Studies on RNA tumor viruses: A possible chemoprophylaxis of
malignancy by the copper complexes of isonicotinic acid hydrazide. Ph.D. Thesis,
Indian Institute of Science, Bangalore, 1978.
Abstracts:
1.
Z. Yin, G.A. Aslanidi, C. Ling, Y. Zhang, C. Ling, M.Q. Tan, M.C. Yoder, and A.
Srivastava. A novel mechanism of transduction of human cells by recombinant AAV
vectors. Submitted for presentation at the 18th Annual Meeting of the American
Society of Gene and Cell Therapy, New Orleans, LA, May, 2015.
2.
Z. Yin, G.A. Aslanidi, C. Ling, Y. Zhang, C. Ling, M.Q. Tan, M.C. Yoder, and A.
Srivastava. Primary human CD34+ hematopoietic stem/progenitor cell (HSPC)
transduction by AAV6 serotype vectors: Strategies for overcoming the donorvariation. Submitted for presentation at the 18th Annual Meeting of the American
Society of Gene and Cell Therapy, New Orleans, LA, May, 2015.
3.
C. Ling, Y. Lu, Y. Zhang, B. Li, W. Ma, G.A. Aslanidi, C. Ling, and A. Srivastava.
Development of Generation X recombinant AAV vectors for human gene therapy.
Submitted for presentation at the 18th Annual Meeting of the American Society of
Gene and Cell Therapy, New Orleans, LA, May, 2015.
4.
C. Ling, Z. Yin, A. Diaz, Y. Zhang, D. Zhang, G.A. Aslanidi, C. Ling, and A. Srivastava.
Generation of improved recombinant AAV3 serotype vectors using AAV3 ITRs and
AAV3 Rep proteins. Submitted for presentation at the 18th Annual Meeting of the
American Society of Gene and Cell Therapy, New Orleans, LA, May, 2015.
5.
Z. Yin, Y. Wang, Y. Zhang, F. Ashby, M. Fajardo, G.A. Aslanidi, C. Ling, A. Srivastava,
and C. Ling. Multifunctional drugs enhance rAAV vector-mediated transgene
expression through different mechanisms in different cell types. Submitted for
37
presentation at the 18th Annual Meeting of the American Society of Gene and Cell
Therapy, New Orleans, LA, May, 2015.
6.
D. Nolasco, K. Van Vliet, D. Markusic, C. Ling, L.-Y. Huang, M. Agbandje-McKenna, A.
Srivastava, and G.A. Aslanidi. Optimization of the capsid of recombinant adenoassociated virus 6 (AAV6) vectors for liver- and muscle-directed gene therapy.
Submitted for presentation at the 18th Annual Meeting of the American Society of
Gene and Cell Therapy, New Orleans, LA, May, 2015.
7.
Y. Colon-Cortes, P. Sharma, C. Ling, M. Abu-Hasan, A. Srivastava, and G.A. Aslanidi.
Development of optimized AAV serotype vectors for the potential gene therapy of
cystic fibrosis. Submitted for presentation at the 18th Annual Meeting of the American
Society of Gene and Cell Therapy, New Orleans, LA, May, 2015.
8.
F. Borel, L. Song, E. Kocabas, H. Sun, Q. Tang, S. Choudhury, G.A. Aslanidi, A.
Srivastava, K. Wagner, M. Esteves, T.R. Flotte, and C. Mueller. Development of
optimized AAV serotype vectors and strategies for the potential gene therapy of
alpha 1 antitrypsin deficiency. Submitted for presentation at the 18 th Annual Meeting
of the American Society of Gene and Cell Therapy, New Orleans, LA, May, 2015.
9.
Y. Wang, Y. Zhang, Y. Lu, L. Wang, Z. Hu, A. Ejjigani, G.V. Aslanidi, L. Zhong, G. Gao C.
Ling, C. Ling, and A. Srivastava. Targeted delivery and suppression of human liver
tumorigenesis by optimized recombinant AAV3 vectors in a murine xenograft model.
Mol. Ther., 22: S29, 2014.
10.
C. Ling, Y. Wang, Y. Zhang, K. Vercauteren, L. Verhoye, Y. Lu, G.V. Aslanidi, L. Zhong,
G. Gao, C. Ling, P. Meuleman, and A. Srivastava. Transduction of primary human
hepatocytes in vitro and in humanized murine livers in vivo by recombinant AAV3
vectors. Mol. Ther., 22: S2, 2014.
11.
L. Zhong, S. Li, M. Li, C. Ling, Q. Su, R. He, A. Srivastava, and G. Gao. Efficient and
targeted transduction of nonhuman primate liver with optimized AAV3B vectors
through systemic delivery. Mol. Ther., 22: S91, 2014.
12.
Y. Zhang, Y. Wang, L. Wang, A. Srivastava, C. Ling, and C. Ling. Delivery of
Trichosanthin-encoding gene induces suppression of human liver tumorigenesis both
in vitro and in vivo. Mol. Ther., 22: S301, 2014.
13.
Y. Wang, A. Srivastava, C. Ling, and C. Ling. The inhibitory effect of various
transfection agents on rAAV vector-mediated transgene expression both in vitro and
in vivo. Mol. Ther., 22: S117, 2014.
14.
G.V. Aslanidi, A.E. Rivers, L. Ortiz, C. Ling, K.V. Vliet, L. Govindasamy, M. AgbandjeMcKenna, and A. Srivastava. Optimization of the capsid of recombinant adenoassociated virus 2 vectors: The final threshold? Mol. Ther., 21: S129, 2013.
15.
B. Li, W. Ma, G.V. Aslanidi, C. Ling, K.V. Vliet, M. Agbandje-McKenna, and A.
Srivastava. Site-directed mutagenesis of surface-exposed lysine residues leads to
improved transduction by recombinant AAV2 and AAV8 vectors in murine
hepatocytes in vivo. Mol. Ther., 21: S208, 2013.
16.
L. Song, M.A. Kauss, E. Kopin, M. Chandra, T. Ul-Hasan, E. Miller, G.R. Jayandharan,
A.E. Rivers, G.V. Aslanidi, C. Ling, B. Li, W. Ma, X. Li, L.M. Andino, L. Zhong, A.F. Tarantal,
M.C. Yoder, K.K. Wong, Jr., M. Tan, S. Chatterjee, and A. Srivastava. Transduction of
murine, nonhuman primate, and human hematopoietic stem cells (HSCs) by
recombinant AAV serotype vectors: Identification of AAV6 as the most efficient
serotype for human HSCs, and further augmentation in transduction efficiency in vitro
38
and in vivo with point-mutations of tyrosine residues in the viral capsid. Mol. Ther., 21:
S209, 2013.
17.
L. Song, X. Li, G.R. Jayandharan, Y. Wang, G.V. Aslanidi, C. Ling, L. Zhong, G. Gao,
M.C. Yoder, C. Ling, M. Tan, and A. Srivastava. High-efficiency transduction of
primary human hematopoietic stem cells and erythroid lineage-restricted expression
by optimized scAAV6 serotype vectors in vitro and in a murine xenograft model in
vivo. Mol. Ther., 21: S126, 2013.
18.
G.V. Aslanidi, A.E. Rivers, L. Ortiz, J. Pandya, K.V. Vliet, M. Agbandje-McKenna, and
A. Srivastava. High-efficiency transduction of primary human monocyte-derived
dendritic cells by recombinant AAV6 vectors containing mutations in surfaceexposed serine and threonine residues. Mol. Ther., 21: S129, 2013.
19.
L. Wang, Y. Wang, G.V. Aslanidi, A. Srivastava, C. Ling, and C. Ling. Pristimerin
enhances recombinant adeno-associated virus serotype 2 vector-mediated
transgene expression both in vitro and in vivo. Mol. Ther., 21: S121, 2013.
20.
Y. Wang, Y. Lu, L. Wang, J.-H. Kim, G.V. Aslanidi, C. Ling, A. Srivastava, and C. Ling.
Functional role of the AAV2 inverted terminal repeat in messenger RNA transport and
transgene expression. Mol. Ther., 21: S30, 2013.
21.
L. Wang, Y. Wang, Y. Lu, G.V. Aslanidi, C. Ling, A. Srivastava, and C. Ling. Productive
life cycle of the AAV2 in the complete absence of a conventional polyadenylation
signal. Mol. Ther., 21: S49, 2013.
22.
C.H. Hakim, Y. Yue, J.-H. Shin, R.R. Williams, K. Zhang, A. Srivastava, B.F. Smith, and D.
Duan. Systemic gene transfer in neonatal dogs using tyrosine mutant AAV-1, -6, and
-9. Mol. Ther., 21: S210, 2013.
23.
M.-J. Chen, Y. Lu, T. Hamazaki, H.-Y. Tsai, K. Erger, T. Conlon, A. Srivastava, M. Brantly,
V. Chiodo, W. Hauswirth, N. Terada, and S. Song. Reprogramming adipose tissuederived mesenchymal stem cells(AT-MSC) into pluripotent stem cells by a mutant
AAV vector. Mol. Ther., 21: S30, 2013.
24.
A. Krishnagopal, S. Hareendran, D. Sen, A. Srivastava, A. Srivastava, and G.R.
Jayandharan. Regulation of host cell DNA binding proteins augment the gene
transfer efficiency of adeno-associated virus (AAV) vectors. Mol. Ther., 21: S128, 2013.
25.
G.V. Aslanidi, A.E. Rivers, L. Ortiz, C. Ling, L. Govindasamy, G.R. Jayandharan, K.V.
Vliet, M. Agbandje-McKenna, and A. Srivastava. Site-directed mutagenesis of
surface-exposed tyrosine, serine, and threonine residues leads to high-efficiency
transduction by recombinant AAV2 vectors. Mol. Ther., 20: S48, 2012.
26.
G.V. Aslanidi, A.E. Rivers, L. Ortiz, C. Ling, L. Govindasamy, G.R. Jayandharan, K.V.
Vliet, M. Agbandje-McKenna, and A. Srivastava. High-efficiency transduction of
primary human monocyte-derived dendritic cells by recombinant AAV2 vectors
containing mutations in surface-exposed serine and threonine residues. Mol. Ther.,
20: S144, 2012.
27.
L. Song, B. Li, Y. Wang, W. Ma, G.V. Aslanidi, C. Ling, M. Tan, and A. Srivastava.
Mechanism of transduction of human hematopoietic cells by recombinant AAV6
vectors. Mol. Ther., 20: S229, 2012.
28.
L. Song, G.R. Jayandharan, B. Li, W. Ma, C. Ling, M. Tan, and A. Srivastava. Highefficiency transduction of primary human hematopoietic stem cells by optimized
AAV6 serotype vectors and erythroid lineage-restricted transcriptional targeting
using the human parvovirus B19 promoter. Mol. Ther., 20: S48, 2012.
39
29.
S. Hareendran, M. Hussain, R.A. Gadkari, S. Govindarajan, D. Sen, B. Balakrishnan, Y.S.
Kumar, V. Kalaivani, B. Ramakrishna, A. Srivastava, N. Srinivasan, A. Srivastava, and
G.R. Jayandharan. Bio-engineering of adeno-associated virus (AAV) serotype 2
capsid at serine/threonine residues improves its transduction efficiency both in vitro
and in vivo. Mol. Ther., 20: S47, 2012.
30.
B. Balakrishnan, D. Sen, S. David, A. Srivastava, A. Srivastava, and G.R. Jayandharan.
Activation of the cellular unfolded protein response by recombinant adenoassociated virus vectors: Implications in gene therapy. Mol. Ther., 20: S142, 2012.
31.
N. Gabriel, R. Duraiswamy, R.A. Gadkari, S. Govindarajan, B. Ramakrishna, A.
Srivastava, N. Srinivasan, A. Srivastava, and G.R. Jayandharan. Targeted
mutagenesis of ubiquitin-binding lysine residues on the adeno-associated virus
(AAV)2 capsid improves its transduction efficiency. Mol. Ther., 20: S146, 2012.
32.
J. Pandya, A. Srivastava, and G.V. Aslanidi. High-efficiency transgene expression in
monocyte-derived dendritic (moDCs) mediated by recombinant adeno-associated
virus vectors containing short subsets of human CD11c promoter. Mol. Ther., 20: S144,
2012.
33.
C. Ling, Y. Wang, L. Song, G.V. Aslanidi, M. Tan, C. Ling, and A. Srivastava. Limitations
of encapsidation of recombinant scAAV2 genomes in different serotype capsids and
their quantitation. Mol. Ther., 20: S47, 2012.
34.
S. Hareendran, N. Gabriel, A. Srivastava, A. Srivastava, and G.R. Jayandharan.
Regulation of AAV-mediated transgene expression by a host cell transcriptional
repressor PARP-1. Mol. Ther., 19: S48, 2011.
35.
W. Ma, B. Li, C. Ling, G.R. Jayandharan, A. Srivastava, and B.J. Byrne. A simple
strategy to achieve high-efficiency transduction by single-stranded AAV vectors in
vitro and in vivo. Mol. Ther., 19: S52, 2011.
36.
A.T. Martino, D.M. Markusic, A. Srivastava, and R.W. Herzog. The AAV2 (Y-F) mutant
capsid causes immune avoidance to killing by capsid specific CD8+ T cells and is
further improved by proteasome inhibition. Mol. Ther., 19: S112, 2011.
37.
G.V. Aslanidi, L. Govindasamy, C. Ling, S. Zolotukhin, M. Agbandje-McKenna, and A.
Srivastava. Site-directed mutagenesis of a surface-exposed serine residue leads to
high-efficiency transduction by recombinant adeno-associated virus 2 vectors. Mol.
Ther., 19: S128, 2011.
38.
G.V. Aslanidi, C. Ling, A.T. Martino, L. Govindasamy, M. Agbandje-McKenna, R.W.
Herzog, and A. Srivastava. High-efficiency transduction of primary human
monocytes-derived dendritic cells (moDCs) by recombinant adeno-associated virus
vectors containing a point mutation in the surface-exposed serine residue. Mol. Ther.,
19: S155, 2011.
39.
Cheng, C. Ling, Y. Dai, L. Glushakova, Y. Lu, S.W.Y. Gee, K.E. McGoogan, G.V.
Aslanidi, M. Park, P.W. Stacpoole, Dietmar Siemann, A. Srivastava, and C. Ling.
Development of optimized AAV3 serotype vectors: Mechanism of high-efficiency
transduction of human liver cancer cells. Mol. Ther., 19: S157, 2011.
40.
G.R. Jayandharan, G.V. Aslanidi, A.T. Martino, S.C. Jahn, G.Q. Perrin, R.W. Herzog,
and A. Srivastava. AAV vector-mediated activation of canonical and alternative NFB pathways in vivo: Implications for innate and adaptive in immune responses and
gene therapy. Mol. Ther., 19: S237, 2011.
40
41.
D.M. Markusic, L.J. Smith, I. Zolotukhin, A. Srivastava, S. Chatterjee, and R.W. Herzog.
Therapeutic expression of Factor IX in a murine hemophilia model using a novel
human stem cell derived AAV serotype. Mol. Ther., 19: S255, 2011.
42.
M. Li, Q. Su, R. He, H. Zhang, T.R. Flotte, A. Srivastava, G. Gao, and L. Zhong.
Development of novel of novel AAV vectors for potential in vivo gene transfer to
hematopoietic stem cells in bone marrow. Mol. Ther., 19: S316, 2011.
43.
H. Petrs-Silva, A. Dinculescu, S.H. Min, L. Zhong, S. Zolotukhin, A. Srivastava, A. Lewin,
and W.W. Hauswirth. Tyrosine mutations in the capsid of AAV vectors alter
transduction properties in the retina. Mol. Ther., 18: S25, 2010.
44.
B.K. Sack, G.R. Jayandharan, L. Zhong, R.W. Herzog, and A. Srivastava. Therapeutic
expression of F.IX at reduced doses using AAV-protein phosphatase 5 helper-virus.
Mol. Ther., 18: S27, 2010.
45.
G.R. Jayandharan, G. Aslanidi, G.Q. Perrin, L. Zhong, A.E. Rivers, A.T. Martino, R.W.
Herzog, and A. Srivastava. Activation of the non-canonical NFvectors: Implications in immune response and gene therapy. Mol. Ther., 18: S141,
2010.
46.
M. Li, G.R. Jayandharan, B. Li, C. Ling, W. Ma, A. Srivastava, and L. Zhong. Role of a
cellular chaperone protein, FKBP52, in uncoating of AAV2 vectors. Mol. Ther., 18:
S143, 2010.
47.
G. Aslanidi, G.Q. Perrin, G.R. Jayandharan, A.E. Rivers, L. Zhong, and A. Srivastava.
Strategies to achieve enhanced transduction of primary human dendritic cells by
AAV2 vectors and reduced cytotoxic T cell response to viral capsids and transgene
products. Mol. Ther., 18: S143, 2010.
48.
A. Martino, D. Markusic, A. Srivastava, and R.W. Herzog. Murine hepatocytes
transduced with Y-F mutant capsid are more resistant to killing by capsid-specific
CD8+ T cells. Mol. Ther., 18: S209, 2010.
49.
J.-H. Shin, Y. Lai, Y. Yue, A. Srivastava, B.F. Smith, and D. Duan. Successful expression
of a R16/17 micro-dystrophin gene in dystrophic dogs with a tyrosine-mutant AAV
vector and a brief course of immune suppression. Mol. Ther., 18: S228, 2010.
50.
Ling, Y. Lu, J.K. Kalsi, G.R. Jayandharan, B. Cheng, S.W.Y. Gee, K.E. McGoogan, L.
Zhong, and A. Srivastava. Identification of human hepatocyte growth factor
receptor as a cellular receptor/co-receptor for AAV3. Mol. Ther., 18: S273, 2010.
51.
Ling, G.R. Jayandharan, B. Li, Y. Lu, W. Ma, and A. Srivastava. Development of the
D[+]-sequence-deleted ssAAV2 vectors: Enhanced transgene expression in vitro and
in vivo. Mol. Ther., 18: S275, 2010.
52.
Y. Lu, C. Ling, G.R. Jayandharan, A.E. Rivers, and A. Srivastava. Involvement of the
glucocorticoid receptor signaling in AAV2 vector-mediated transgene expression.
Mol. Ther., 18: S276, 2010.
53.
G.R. Jayandharan, G. Aslanidi, G.Q. Perrin, L. Zhong, A.E. Rivers, A.T. Martino, R.W.
Herzog, and A. Srivastava. Activation of the non-canonical NFvectors: Implications in immune response and gene therapy. XIIIth Parvovirus
Workshop, Helsinki, Finland, June, 2010.
54.
G. Aslanidi, G.Q. Perrin, G.R. Jayandharan, A.E. Rivers, L. Zhong, and A. Srivastava.
Strategies to achieve enhanced transduction of primary human dendritic cells by
AAV2 vectors and reduced cytotoxic T cell response to viral capsids and transgene
products. XIIIth Parvovirus Workshop, Helsinki, Finland, June, 2010.
41
55.
Ling, Y. Lu, J.K. Kalsi, G.R. Jayandharan, B. Cheng, S.W.Y. Gee, K.E. McGoogan, L.
Zhong, and A. Srivastava. Human hepatocyte growth factor receptor is a cellular
co-receptor for AAV3. XIIIth Parvovirus Workshop, Helsinki, Finland, June, 2010.
56.
Ling, G.R. Jayandharan, B. Li, Y. Lu, W. Ma, and A. Srivastava. Development of the
D[+]-sequence-deleted ssAAV2 vectors: Enhanced transgene expression in vitro and
in vivo. XIIIth Parvovirus Workshop, Helsinki, Finland, June, 2010.
57.
Y. Lu, C. Ling, G.R. Jayandharan, A.E. Rivers, and A. Srivastava. Involvement of the
glucocorticoid receptor signaling in AAV2 vector-mediated transgene expression.
XIIIth Parvovirus Workshop, Helsinki, Finland, June, 2010.
58.
L. Zhong, M. Li, B. Li, and A. Srivastava. High-efficiency transduction of murine
fibroblasts by tyrosine-mutant AAV2 vectors: Critical requirement of a cellular
chaperone protein, FKBP52, for intracellular trafficking and nuclear transport. Mol.
Ther., 17: S36, 2009.
59.
J. Silver, G.R. Jayandharan, P. Cruz, M. Elder, A. Srivastava, and T.R. Flotte.
Recombinant AAV vector-mediated gene delivery for the potential treatment of
adenosine deaminase deficiency. Mol. Ther., 17: S117, 2009.
60.
G.R. Jayandharan, L. Zhong, B. Li, B. Sack, R.W. Herzog, and A. Srivastava. Strategies
for improving the transduction efficiency of single-stranded adeno-associated virus
vectors in murine hepatocytes in vivo. Mol. Ther., 17: S145, 2009.
61.
L. Zhong, B. Li, M. Li, I. Zolotukhin, R.W. Herzog, S. Zolotukhin, and A. Srivastava. Highefficiency transduction of human cells in vitro and murine hepatocytes in vivo at
further reduced doses of recombinant adeno-associated virus 2 vectors containing
multiple-mutations in surface-exposed tyrosine residues. Mol. Ther., 17: S145, 2009.
62.
G.R. Jayandharan, A.E. Rivers, C. Ling, L.M. Andino, L. Zhong, and A. Srivastava.
Human hematopoietic stem cell transduction by AAV vectors: Identification of AAV6
as the most efficient serotype, and further augmentation in transduction efficiency
with point-mutations at tyrosine residues 705 and 731 in the viral capsid. Mol. Ther.,
17: S176, 2009.
63.
Qiao, H. Zheng, Z. Yuan, J. Li, L. Zhong, A. Srivastava, J. Li, and X. Xiao. Comparison
of transduction efficiency of tyrosine-mutant AAV vectors in muscle. Mol. Ther., 17:
S175, 2009.
64.
W. Zhang, Y. Yue, A. Ghosh, G.R. Jayandharan, L. Zhong, S. Zolotukhin, Y. Lai, A.
Srivastava, and D. Duan. Novel tyrosine mutant vectors expand the utilities of AAVmediated muscle gene therapy. Mol. Ther., 17: S176, 2009.
65.
M.A. Kauss, L.J. Smith, L. Zhong, K.K. Wong, A. Srivastava, and S. Chatterjee. Tyrosinemodified AAV2 vectors display enhanced transduction of human hematopoietic
stem cells. Mol. Ther., 17: S178, 2009.
66.
L.G. Glushakova, M.J. Lisankie, E.B. Eruslanov, C. Ojano-Dirain, I. Zolotukhin, C. Liu, A.
Srivastava, and P.W. Stacpoole.
High-efficiency transduction of human
hepatoblastoma and hepatocellular carcinoma cells by the wild-type and the
tyrosine-mutant AAV3 serotype vectors. Mol. Ther., 17: S179, 2009.
67.
D.M. Markusic, M. Cooper, I. Zolotukhin, L. Zhong, A. Srivastava, and R.W. Herzog.
Novel AAV2 tyrosine mutant capsids provide long-term therapeutic Factor IX
expression in a difficult to tolerize murine hemophilia model. Mol. Ther., 17: S292, 2009.
42
68.
A. Srivastava. Intracellular fate of recombinant AAV vectors: Implications in immune
response and gene therapy. Cold Spring Harbor Meeting on In Vivo Barriers to Gene
Delivery, Cold Spring Harbor, NY, p7, 2009.
69.
Z. Han, L. Zhong, N. Maina, Z. Hu, X. Li, N.S. Chouthai, D. Bischof, K.A. Weigel-Van Aken,
W.B. Slayton, M.C. Yoder, and A. Srivastava. Recombinant adeno-associated virus 2
vector genomes are stably integrated into chromosomes following transduction of
murine hematopoietic stem cells. Mol. Ther., 16: S3, 2008.
70.
L. Zhong, B. Li, C.S. Mah, L. Govindasamy, M. Agbandje-McKenna, M. Cooper, R.W.
Herzog, I. Zolotukhin, K.H. Warrington, Jr., K.A. Weigel-Van Aken, J.A. Hobbs, S.
Zolotukhin, N. Muzyczka, and A. Srivastava. Next generation of recombinant adenoassociated virus 2 vectors: Point mutations in tyrosine residues lead to high-efficiency
transduction at lower vector doses. Mol. Ther., 16: S144, 2008.
71.
G.R. Jayandharan, L. Zhong, B. Li, B. Kachniarz, and A. Srivastava. Strategies for
improving the transduction efficiency of single-stranded adeno-associated virus
vectors in vitro and in vivo. Mol. Ther., 16: S251, 2008.
72.
N. Maina, L. Zhong, X. Li, W. Zhao, Z. Han, D. Bischof, G. Aslanidi, S. Zolotukhin, K.A.
Weigel-Van Aken, A.E. Rivers, W.B. Slayton, M.C. Yoder, and A. Srivastava.
Optimization of recombinant adeno-associated virus vectors for human -globin
gene transfer and transgene expression. Mol. Ther., 16: S296, 2008.
73.
G.R. Jayandharan, L. Zhong, B. Li, B. Kachniarz, and A. Srivastava. Strategies for
improving the transduction efficiency of single-stranded adeno-associated virus
vectors in vitro and in vivo. XIIth Parvovirus Workshop, Cordoba, Spain, June, 2008.
74.
L. Zhong, B. Li, C.S. Mah, L. Govindasamy, M. Agbandje-McKenna, M. Cooper, R.W.
Herzog, I. Zolotukhin, K.H. Warrington, Jr., K.A. Weigel-Van Aken, J.A. Hobbs, S.
Zolotukhin, N. Muzyczka, and A. Srivastava. Next generation of recombinant adenoassociated virus 2 vectors: Point mutations in tyrosine residues lead to high-efficiency
transduction and production of therapeutic levels of coagulation factor IX at lower
vector doses. XIIth Parvovirus Workshop, Cordoba, Spain, June, 2008.
75.
N. Maina, W. Zhao, X. Li, Z. Han, L. Zhong, D. Bischof, G. Aslanidi, S. Zolotukhin, W.
Slayton, and A. Srivastava. Adeno-associated virus-mediated gene transfer: The
combined use of self-complementary AAV vectors and the parvovirus B19 promoter
leads to expression of therapeutic levels of the human beta-globin gene. Mol. Ther.,
15: S317, 2007.
76.
Z. Han, K. Berendzen, L. Zhong, N. Chouthai, W. Zhao, N. Maina, A. Srivastava, and
P.W. Stacpoole. Optimization of delivery and expression of the pyruvate
dehydrogenase E1 alpha subunit gene using self-complementary adeno-associated
virus serotype vectors. Mol. Ther., 15: S326, 2007.
77.
N. Maina, Z. Han, X. Li, W. Zhao, L. Zhong, Z. Hu, W. Slayton, and A. Srivastava.
Strategies for improving adeno-associated virus vector-mediated gene transfer in
primary murine hematopoietic stem cells in vivo. Mol. Ther., 15: S322, 2007.
78.
L. Zhong, B. Li, S. Zolotukhin, L. Govindasamy, M. Agbandje-McKenna, and A.
Srivastava. Adeno-associated virus 2-mediated gene transfer: Tyrosinephosphorylation of capsid proteins and its consequences on transgene expression.
Mol. Ther., 15: S149, 2007.
79.
Z. Han, A. Srivastava, and P.W. Stacpoole. Pyruvate dehydrogenase complex
deficiency caused by the ubiquitin-proteasome system-mediated degradation in
E1 subunit. Mol. Ther., 13: S86, 2006.
43
80.
Z. Han, M. Gorbatyuk, J. Thomas Jr, K.M. Berendzen, A.S. Lewin, A. Srivastava, and
P.W. Stacpoole. Down-regulation of rat pyruvate dehydrogenase E1a mRNA gene
expression by self-complementary AAV-mediated small interfering RNA delivery. Mol.
Ther., 13: S124, 2006.
81.
J. Wu, W. Zhao, L. Zhong, K. H. Warrington, Jr., and A. Srivastava. Self-complementary
adeno-associated virus vectors: Packaging capacity and purity. Mol. Ther., 13: S286,
2006.
82.
L. Zhong, W. Zhao, J. Wu, B. Li, and A. Srivastava. Adeno-associated virus 2-mediated
gene transfer: A complex interaction between epidermal growth factor receptor
protein tyrosine kinase signaling and ubiquitin/proteasome pathway in transgene
expression. Mol. Ther., 13: S3, 2006.
83.
Z. Han, M. Gorbatyuk, J. Thomas Jr, K.M. Berendzen, A.S. Lewin, A. Srivastava, and
P.W. Stacpoole. Down-regulation of rat pyruvate dehydrogenase E1a mRNA gene
expression by self-complementary AAV-mediated small interfering RNA delivery. XIth
Parvovirus Workshop, Les Diablerets, Switzerland, August, 2006.
84.
J. Wu, W. Zhao, L. Zhong, K.A. Weigel-Kelley, K. H. Warrington, Jr., and A. Srivastava.
Self-complementary adeno-associated virus vectors: Packaging capacity and role
of Rep proteins in vector purity. XIth Parvovirus Workshop, Les Diablerets, Switzerland,
August, 2006.
85.
L. Zhong, W. Zhao, J. Wu, B. Li, and A. Srivastava. Adeno-associated virus 2-mediated
gene transfer: A dual role of epidermal growth factor receptor protein tyrosine kinase
signaling in ubiquitination of viral capsids and viral second-strand DNA synthesis. XIth
Parvovirus Workshop, Les Diablerets, Switzerland, August, 2006.
86.
W. Zhao, J. Wu, L. Zhong, and A. Srivastava. AAV-mediated gene transfer:
Identification of a cellular protein serine/threonine phosphatase involved in
augmenting vector transduction efficiency. XIth Parvovirus Workshop, Les Diablerets,
Switzerland, August, 2006.
87.
N. Maina, W. Zhao, L. Zhong, G. Aslanidi, S. Zolotukhin, and A. Srivastava. AAVmediated beta-globin gene transfer: The combined use of self-complementary
vectors and the parvovirus B19p6 promoter significantly augments the transgene
expression. XIth Parvovirus Workshop, Les Diablerets, Switzerland, August, 2006.
88.
L. Zhong, X. Zhou, Y. Li, K. Qing, R.J. Samulski, and A. Srivastava. Single-polarity
recombinant adeno-associated virus 2 vector-mediated transgene expression in
vitro and in vivo: Mechanism of transduction. Mol. Ther., 11: S5, 2005.
89.
L. Zhong, W. Li, Y. Li, K. Qing, M.C. Yoder MC, and A. Srivastava. Evaluation of
primitive murine hematopoietic stem and progenitor cell transduction in vitro and in
vivo by recombinant adeno-associated virus vectors based on serotypes 1 through
5. Mol. Ther., 11: S155, 2005.
90.
W. Zhao, L. Zhong, J. Wu, L. Chen, K. Qing, K.A. Weigel-Kelley, S.H. Larsen SH, and A.
Srivastava. An additional role of cellular FKBP52 in recombinant adeno-associated
virus 2 vector-mediated gene transfer and transgene expression. Mol. Ther., 11: S7,
2005.
91.
L. Zhong, W. Li, Z, Yang, L.Y. Chen, Y. Li, K.Y. Qing, K.A. Weigel-Kelley, M.C. Yoder, W.
Shou and A. Srivastava. Improved transduction of primary murine hepatocytes by
recombinant adeno-associated virus 2 vectors in vivo. Mol. Ther., 9: S376, 2004.
44
92.
Z. Yang, L. Zhong, W. Li, K.Y. Qing, M.Q. Tan, Y. Li, L.Y. Chen, J. Hansen, M.C. Yoder,
W. Shou and A. Srivastava. Impaired intracellular trafficking and uncoating of
recombinant adeno-associated virus 2 vectors limit efficient transduction of primary
murine hematopoietic cells. Mol. Ther., 9: S116, 2004.
93.
L. Zhong, W. Li, Z, Yang, L.Y. Chen, Y. Li, K.Y. Qing, K.A. Weigel-Kelley, M.C. Yoder, W.
Shou and A. Srivastava. Improved transduction of primary murine hepatocytes by
recombinant adeno-associated virus 2 vectors in vivo. p. 136. Xth Parvovirus
Workshop, St. Petersburg Beach, Florida, 2004.
94.
L. Zhong, W. Li, Z, Yang, L.Y. Chen, Y. Li, K.Y. Qing, K.A. Weigel-Kelley, M.C. Yoder, W.
Shou and A. Srivastava. Improved transduction of primary murine hepatocytes by
recombinant adeno-associated virus 2 vectors in vivo. 77. Xth Parvovirus Workshop,
St. Petersburg Beach, Florida, 2004.
95.
Z. Yang, L. Zhong, W. Li, K.Y. Qing, M.Q. Tan, Y. Li, L.Y. Chen, J. Hansen, M.C. Yoder,
W. Shou and A. Srivastava. Impaired intracellular trafficking and uncoating of
recombinant adeno-associated virus 2 vectors limit efficient transduction of primary
murine hematopoietic cells. p. 117. Xth Parvovirus Workshop, St. Petersburg Beach,
Florida, 2004.
96.
K.A. Weigel-Kelley, and A. Srivastava. Role of actin cytoskeleton and small GTPsae
Rap1 in the co1 integrin for human parvovirus B19 entry. p.
44. Xth Parvovirus Workshop, St. Petersburg Beach, Florida, 2004.
97.
K.A. Weigel-Kelley, M.C. Yoder and A. Srivastava. Recombinant human parvovirus
B19 vectorcellular co-receptor for vector entry. Mol. Ther., 7: S472, 2003.
98.
L. Zhong, K.Y. Qing, Y. Si, L. Chen and A. Srivastava. Adeno-associated virus 2mediated gene transfer: Role of cellular heat-shock protein 90 in transgene
expression. Mol. Ther., 7: S13, 2003.
99.
K.Y. Qing, Z. Yang, L. Zhong, W. Li, L. Chen, M.C. Yoder, W. Shou and A. Srivastava.
Adeno-associated virus 2-mediated gene transfer and transgene expression in
primary hematopoietic stem and progenitor cells from FKBP52-knockout mice. Mol.
Ther., 7: S14, 2003.
100.
K.Y. Qing, M.Q. Tan and A. Srivastava. Adeno-associated virus 2-mediated gene
transfer: Role of T-cell protein tyrosine phosphatase in transgene expression in
established cell lines in vitro and in transgenic mice in vivo. Mol. Ther., 5: S2, 2002.
101.
K.Y. Qing, M.Q. Tan and A. Srivastava. Adeno-associated virus 2-mediated gene
transfer: Role of T-cell protein tyrosine phosphatase in transgene expression in
established and primary cells in vitro and in transgenic mice in vivo. IXth Parvovirus
Workshop, Bologna, Italy, 2002.
102.
K.A. Weigel-Kelley, M.C. Yoder and A. Srivastava. Multiple b1 integrins serve as
cellular co-receptors for infection by the human parvovirus B19. IXth Parvovirus
Workshop, Bologna, Italy, 2002.
103.
J. Hansen, K.Y. Qing and A. Srivastava. Adeno-associated virus 2-mediated gene
transfer: Altered endocytic processing enhances transduction efficiency in murine
fibroblasts. Mol. Ther., 3: S186, 2001.
104.
M.Q. Tan, K.Y. Qing, M.C. Yoder, and A. Srivastava. AAV-mediated transduction and
erythroid lineage-restricted, long-term expression of a normal human -globin gene
in hematopoietic cells from homozygous -thalassemic mice. Mol. Ther., 1: S100, 2000.
45
105.
K.Y. Qing, J. Hansen, and A. Srivastava. AAV-mediated gene transfer: Role of cellular
FKBP52 protein in transgene expression. Mol. Ther., 1: S189, 2000.
106.
H.-J. Kwon, K.A. Weigel-Kelley, J. Hansen, K.Y. Qing, and A. Srivastava. AAVmediated gene transfer: Effect on MHC Class II gene expression. Mol. Ther., 1: S190,
2000.
107.
K.A. Weigel-Kelley, M.C. Yoder, and A. Srivastava. Recombinant human parvovirus
B19 vectors: Erythrocyte P antigen is necessary but not sufficient for successful
transduction of hematopoietic cells. Mol. Ther., 1: S283, 2000.
108.
M.Q. Tan, K.Y. Qing, J. Hansen, M.C. Yoder, and A. Srivastava. AAV-mediated
transduction of murine hematopoietic progenitor cells in vitro and in vivo. Mol. Ther.,
1: S285, 2000.
109.
M.Q. Tan, K.Y. Qing, M.C. Yoder, and A. Srivastava. AAV-mediated transduction and
erythroid lineage-restricted, long-term expression of a normal human -globin gene
in hematopoietic cells from homozygous -thalassemic mice. p. 218. VIIIth Parvovirus
Workshop, Mont-Tremblant, Qubec, Canada, 2000.
110.
K.Y. Qing, J. Hansen, and A. Srivastava. AAV-mediated gene transfer: Role of cellular
FKBP52 protein in transgene expression. p. 72. VIIIth Parvovirus Workshop, MontTremblant, Qubec, Canada, 2000.
111.
H.-J. Kwon, K.A. Weigel-Kelley, J. Hansen, K.Y. Qing, and A. Srivastava. AAVmediated gene transfer: Effect on MHC Class II gene expression. p. 76. VIIIth
Parvovirus Workshop, Mont-Tremblant, Qubec, Canada, 2000.
112.
K.A. Weigel-Kelley, M.C. Yoder, and A. Srivastava. Recombinant human parvovirus
B19 vectors: Erythrocyte P antigen is necessary but not sufficient for successful
transduction of hematopoietic cells. p. 48. VIIIth Parvovirus Workshop, MontTremblant, Qubec, Canada, 2000.
113.
M.Q. Tan, K.Y. Qing, J. Hansen, M.C. Yoder, and A. Srivastava. AAV-mediated
transduction of murine hematopoietic progenitor cells in vitro and in vivo. p. 215.
VIIIth Parvovirus Workshop, Mont-Tremblant, Qubec, Canada, 2000.
114.
M.-Q. Tan, K.Y. Qing, M.C. Yoder and A. Srivastava. Adeno-associated virus 2mediated transduction of primary murine hematopoietic progenitor cells in vitro and
in vivo. Blood, 94: 356a, 1999.
115.
J. Hansen, K.Y. Qing, H.-J. Kwon, C. Mah and A. Srivastava. Impaired intracellular
trafficking of adeno-associated virus 2 vectors limits efficient transduction of murine
fibroblasts. Blood, 94: 410b, 1999.
116.
H.-J. Kwon, J. Hansen, K.Y. Qing, B. Khuntirat, D.B. Donner and A. Srivastava.
Identification of cellular homologs of the D-sequence in the adeno-associated virus
2 and the role of their cognate proteins in viral transduction. Blood, 94: 413b, 1999.
117.
X.-S. Wang, B. Khuntirat, K.Y. Qing, S. Ponnazhagan, D.M. Kube, S.Z. Zhou, V.J. Dwarki
and A. Srivastava. Characterization of the wild-type adeno-associated virus 2-like
particles generated during recombinant viral vector production and strategies for
their elimination. American Society for Gene Therapy. Seattle, WA, 1998.
118.
X.-S. Wang, K.Y. Qing, K. Hiatt, C. Mah, M.C. Yoder and A. Srivastava.
Characterization of recombinant adeno-associated virus 2 vector integration
sequences in primary human bone marrow-derived CD34+ hematopoietic
progenitor cells. American Society for Gene Therapy. Seattle, WA, 1998.
46
119.
Mah, K.Y. Qing, B. Khuntirat, S. Ponnazhagan, X.-S. Wang, D.M. Kube, M.C. Yoder and
A. Srivastava. Adeno-associated virus 2-mediated gene transfer: Role of epidermal
growth factor receptor protein tyrosine kinase in transgene expression. American
Society for Gene Therapy. Seattle, WA, 1998.
120.
S. Ponnazhagan, K.A. Weigel, S.P. Raikwar, M.C. Yoder and A. Srivastava.
Development of human parvovirus B19 vectors: Erythroid cell-specific delivery and
expression of transduced genes. American Society for Gene Therapy. Seattle, WA,
1998.
121.
A. Srivastava. Role of cellular proteins in adeno-associated virus 2-mediated gene
transfer. American Society for Gene Therapy. Seattle, WA, 1998.
122.
Khuntirat, A. Srivastava, S.R. Raikwar and R.H. Schloemer. Human liver cell-specific
transgene expression by recombinant adeno-associated virus 2 vectors. Blood, 92:
149a, 1998.
123.
K.A. Weigel, D.M. Kube and A. Srivastava. Human endothelial cell-specific transgene
expression mediated by a recombinant adeno-associated virus 2-parvovirus B19
hybrid vector. Blood, 92: 382b, 1998.
124.
X.-S. Wang, K.Y. Qing, K. Hiatt, C. Mah, M.C. Yoder and A. Srivastava.
Characterization of recombinant adeno-associated virus 2 vector integration
sequences in primary human bone marrow-derived CD34+ hematopoietic
progenitor cells. Blood, 92: 382b, 1998.
125.
Mah, K.Y. Qing, B. Khuntirat, S. Ponnazhagan, X.-S. Wang, D.M. Kube, M.C. Yoder and
A. Srivastava. Adeno-associated virus 2-mediated gene transfer: Role of epidermal
growth factor receptor protein tyrosine kinase in transgene expression. Blood, 92:
150a, 1998.
126.
K.Y. Qing, C. Mah, J. Hansen, S.Z. Zhou, V.J. Dwarki and A. Srivastava. Human
fibroblast growth factor receptor 1 is a co-receptor for infection by adenoassociated virus 2. Blood, 92: 150a, 1998.
127.
A. Srivastava, S. Ponnazhagan, X.-S. Wang, K.Y. Qing, B. Khuntirat, D.M. Kube, C. Mah,
and M.C. Yoder. AAV and parvovirus B19 vectors for human gene therapy. VIIth
International Parvovirus Workshop, Heidelberg, Germany, 1997.
128.
S. Ponnazhagan, P. Mukherjee, X.-S. Wang, K.Y. Qing, D.M. Kube, C. Kurpad, M.C.
Yoder, E.F. Srour and A. Srivastava. Adeno-associated virus 2-mediated transduction
of primary human bone marrow-derived CD34+ hematopoietic progenitor cells:
Donor variation and correlation of transgene expression with cellular differentiation.
VIIth International Parvovirus Workshop, Heidelberg, Germany, 1997.
129.
S. Ponnazhagan, M.C. Yoder and A. Srivastava. Development of parvovirus B19
vectors: Erythroid cell-specific delivery and expression of transduced genes. VIIth
International Parvovirus Workshop, Heidelberg, Germany, 1997.
130.
X.-S, Wang and A. Srivastava. Rescue and autonomous replication of the AAV
genome in human 293 cells: Mutational analyses of Rep and YY-1 binding sites in the
AAVp5 promoter sequences. VIIth International Parvovirus Workshop, Heidelberg,
Germany, 1997.
131.
X.-S. Wang and A. Srivastava. Characterization of the wild-type "AAV-like" particles
generated during recombinant AAV vector production.
VIIth International
Parvovirus Workshop, Heidelberg, Germany, 1997.
47
132.
X.-S. Wang and A. Srivastava. Characterization of integration sites of recombinant
AAV genomes in human cells. VIIth International Parvovirus Workshop, Heidelberg,
Germany, 1997.
133.
K.Y. Qing, X.-S. Wang, D.M. Kube, S. Ponnazhagan, A. Bajpai and A. Srivastava. Role
of tyrosine phosphorylation of a cellular protein in AAV-mediated transgene
expression. VIIth International Parvovirus Workshop, Heidelberg, Germany, 1997.
134.
K.Y. Qing, X.-S. Wang, B. Khuntirat, C. Mah, S. Ponnazhagan, S.Z. Zhou, V. Dwarki and
A. Srivastava. Tyrosine phosphorylation of the cellular D-BP correlates with AAVmediated transgene expression in human cells in vitro and murine cells in vivo. VIIth
International Parvovirus Workshop, Heidelberg, Germany, 1997.
135.
D.M. Kube, S. Ponnazhagan and A. Srivastava. Encapsidation of AAV Rep proteins
in progeny virions: Wild-type and recombinant AAV-mediated growth inhibition of
primary human cells. VIIth International Parvovirus Workshop, Heidelberg, Germany,
1997.
136.
X.-S. Wang and A. Srivastava. Parvovirus B19 NS-1 gene is embryonic-lethal in
transgenic mice. VIIth International Parvovirus Workshop, Heidelberg, Germany,
1997.
137.
S. Ponnazhagan, M.C. Yoder and A. Srivastava. Development of human parvovirus
B19 vectors: Erythroid cell-specific delivery and expression of transduced genes.
Blood, 90: 602a, 1997.
138.
K.Y. Qing, X.-S. Wang, D.M. Kube, S. Ponnazhagan, A. Bajpai and A. Srivastava. Role
of tyrosine phosphorylation of a cellular protein in AAV-mediated transgene
expression. Blood, 90: 120a, 1997.
139.
K.Y. Qing, X.-S. Wang, B. Khuntirat, C. Mah, S. Ponnazhagan, S.Z. Zhou, V. Dwarki and
A. Srivastava. Tyrosine phosphorylation of the cellular D-BP correlates with AAVmediated transgene expression in human cells in vitro and murine cells in vivo. Blood,
90: 120a, 1997.
140.
X.-S. Wang and A. Srivastava. Parvovirus B19 NS-1 gene is embryonic-lethal in
transgenic mice. Blood, 90: 157b, 1997.
141.
S. Ponnazhagan, P. Mukherjee, X.-S. Wang, C. Kurpad, M.C. Yoder, E.F. Srour and A.
Srivastava. Adeno-associated virus 2-mediated transduction of primary human bone
marrow-derived CD34+ hematopoietic progenitor cells: Donor variation and
correlation of expression with cellular differentiation. Blood, 88: 133a, 1996.
142.
S. Ponnazhagan, M.C. Yoder and A. Srivastava. Adeno-associated virus 2-mediated
transduction of murine repopulating hematopoietic stem cells and long-term
expression of a human globin gene in vivo. Blood, 88: 134a, 1996.
143.
N.C. Munshi, L.M. Ding, L. Dahe, J. Kornbluth, S. Naugler, D. Mahavi and A. Srivastava.
GM-CSF transduction of the tumor cells provides lasting immune response in multiple
myeloma. Blood, 88: 585a, 1996.
144.
K.Y. Qing, T. Bachelot, P. Mukherjee, L. Peng, X.-S. Wang, M.C. Yoder, P. Leboulch
and A. Srivastava. Adeno-associated virus 2-mediated transfer of ecotropic
retrovirus receptor cDNA augments retroviral transduction of established and primary
human cells. Blood, 88: 686a, 1996.
145.
A. Srivastava, X.-S. Wang, S. Ponnazhagan, S.Z. Zhou, D.M. Kube and M.C. Yoder.
Parvovirus-based vectors for human gene therapy. VIth Parvovirus Workshop,
Montpellier, France, 1995.
48
146.
X.-S. Wang, M.C. Yoder, S.Z. Zhou and A. Srivastava. Parvovirus B19p6 promoter
confers autonomous replication-competence as well as erythroid-specificity to AAV
in primary human hematopoietic progenitor cells. VIth Parvovirus Workshop,
Montpellier, France, 1995.
147.
X.-S. Wang, S. Ponnazhagan and A. Srivastava. Rescue, replication, and packaging
signals of the AAV genome. VIth Parvovirus Workshop, Montpellier, France, 1995.
148.
X.-S. Wang and A. Srivastava. A novel terminal resolution-like site in the AAV genome.
VIth Parvovirus Workshop, Montpellier, France, 1995.
149.
S. Ponnazhangan, X.-S. Wang, M.J. Woody, F. Luo, L.Y. Kang, M.L. Nallari, N.C. Munshi,
S.Z. Zhou and A. Srivastava. Differential expression from parvovirus B19p6 promoter
following plasmid transfection and recombinant AAV infection in human cells:
Megakaryocytic leukemia cells are non-permissive for AAV infection. VIth Parvovirus
Workshop, Montpellier, France, 1995.
150.
S. Ponnazhagan, M.J. Woody, X.-S. Wang, S.Z. Zhou and A. Srivastava. Transcriptional
transactivation of parvovirus B19 promoters in non-permissive human cells by
adenovirus 2. VIth Parvovirus Workshop, Montpellier, France, 1995.
151.
D.M. Kube, S. Ponnazhagan and A. Srivastava. AAV-mediated cytopathic effect on
primary human bone marrow stromal cells. VIth Parvovirus Workshop, Montpellier,
France, 1995.
152.
S. Ponnazhagan, X.-S. Wang and A. Srivastava. Alternative strategies for generating
recombinant AAV vectors. VIth Parvovirus Workshop, Montpellier, 1995.
153.
S. Ponnazhagan, X.-S. Wang, A. Srivastava and M.C. Yoder. Adeno-associated virus
2-mediated gene transfer and expression in murine hematopoietic progenitor cells
in vivo. Blood, 86:240a, 1995.
154.
S. Ponnazhagan, M.J. Woody, X.-S. Wang, S.Z. Zhou and A. Srivastava. Transcriptional
transactivation of parvovirus B19 promoters in non-permissive human cells by
adenovirus 2. Blood, 86: 481a, 1995.
155.
D.M. Kube, S. Ponnazhagan and A. Srivastava. AAV-mediated cytopathic effect on
primary human bone marrow stromal cells. Blood, 86: 1000a, 1995.
156.
H.E. Broxmeyer, S. Cooper, M. Etienne-Julan, X.-S. Wang, S. Ponnazhagan and A.
Srivastava. Adeno-associated viral vector shows differential expression in populations
of immature and mature myeloid progenitor cells and is stably expressed after ex
vivo expansion of the progenitors. Exp. Hematol., 23: 900, 1995.
157.
N.C. Munshi, L.M. Ding, J. Kornbluth, S. Naugler, R. Saylors, R. Iyengar, A. Srivastava,
R. Hoover and B. Barlogie. Gene therapy strategies for the treatment of multiple
myeloma. Blood, 84: 172a, 1994.
158.
X.-S. Wang, M.C. Yoder, S.Z. Zhou and A. Srivastava. Parvovirus B19p6 promoter
imparts replication-competence as well as erythroid cell-specificity to a recombinant
adeno-associated virus 2 in human hematopoietic progenitor cells. Blood, 84: 266a,
1994.
159.
S. Ponnazhagan, X.-S. Wang, L.Y. Kang, M.J. Woody, M.L. Nallari, N.C. Munshi, S.Z.
Zhou and A. Srivastava. Transduction of human hematopoietic cells by the adenoassociated virus 2 vectors is receptor-mediated. Blood, 84: 742a, 1994.
160.
A. Srivastava, S.Z. Zhou, P. Nahreini, H.E. Broxmeyer and R. Hoffman. Parvovirusmediated gene transfer in murine and human hematopoietic progenitor and stem
cells. 5th Parvovirus Workshop, Crystal River, FL, 1993.
49
161.
S.Z. Zhou, N.C. Munshi, S.L. Myers and A. Srivastava. Parvovirus B19 infection in
patients with rheumatoid arthritis. 5th Parvovirus Workshop, Crystal River, FL, 1993.
162.
S. Ponnazhagan, M.L. Nallari and A. Srivastava. Suppression of the human -globin
gene expression by transduction of anti-sense -globin DNA sequences mediated by
a recombinant adeno-associated virus 2 vector. 5th Parvovirus Workshop, Crystal
River, FL, 1993.
163.
Luo, S.Z. Zhou and A. Srivastava. Adeno-associated virus 2-mediated transduction
and functional expression of a gene encoding the human granulocyte-macrophage
colony-stimulating factor. 5th Parvovirus Workshop, Crystal River, FL, 1993.
164.
S.Z. Zhou and A. Srivastava. Adeno-associated virus 2-mediated transduction and
erythroid cell-specific expression of a human -globin gene. 5th Parvovirus Workshop,
Crystal River, FL, 1993.
165.
S.Z. Zhou, S. Ponnazhagan, X-S. Wang, P. Nahreini and A. Srivastava. The adenoassociated virus 2 rep gene is insufficient to impart site-specificity of viral integration
in human aneuploid cells. 5th Parvovirus Workshop, Crystal River, FL, 1993.
166.
S.Z. Zhou, N.C. Munshi, S.L. Myers and A. Srivastava. Parvovirus B19 infection in
patients with rheumatoid arthritis. Blood, 82: 96a, 1993.
167.
S. Ponnazhagan, M.L. Nallari and A. Srivastava. Suppression of the human -globin
gene expression by transduction of anti-sense -globin DNA sequences mediated by
a recombinant adeno-associated virus 2 vector. Blood, 82: 303a, 1993.
168.
Luo, S.Z. Zhou, S. Cooper, N.C. Munshi, H.S. Boswell, H.E. Broxmeyer and A. Srivastava.
Adeno-associated virus 2-mediated transduction and functional expression of a
gene encoding the human granulocyte-macrophage colony-stimulating factor.
Blood, 82: 303a, 1993.
169.
S.Z. Zhou, Q. Li, G. Stamatoyannopoulos and A. Srivastava. Adeno-associated virus
2-mediated transduction and erythroid cell-specific expression of a human -globin
gene. Blood, 82: 346a, 1993.
170.
S.Z. Zhou, S. Cooper, L.Y. Kang, A. Srivastava and H.E. Broxmeyer. Adeno-associated
virus 2-mediated gene transfer in hematopoietic progenitor cells in human umbilical
cord blood. Blood, 82: 303a, 1993.
171.
M.C. Yoder, L.Y. Kang, S.Z. Zhou, F. Luo and A. Srivastava. In vivo gene transfer in
murine hematopoietic reconstituting stem cells mediated by the adeno-associated
virus 2-based vectors. Blood, 82: 347a, 1993.
172.
A. Srivastava. Parvoviruses as a novel vector for gene transfer in human cells.
Research Fellowship Symposium, American Heart Association, Atlanta, GA, 1993.
173.
S.Z. Zhou, N.C. Munshi, S.L. Myers and A. Srivastava. Infectious parvovirus B19 in
rheumatoid arthritis. Indiana Branch - American Society for Microbiology Annual
Meeting, Indianapolis, IN, 1992.
174.
X.-L. Sun, B.R. Murphy, A. Srivastava and A.C. Antony. Adeno-associated virus 2
(AAV)-mediated gene transfer: Stable transduction of folate receptor (FR) cDNA in
the sense and anti-sense orientation into human cells leading to modulation of
constitutively over-expressed endogenous genes. Blood, 80: 306a, 1992.
175.
A. Srivastava, S.Z. Zhou, J.E. Brandt, N.C. Munshi, P. Nahreini and R. Hoffman.
Parvovirus-mediated gene transfer in primitive human hematopoietic progenitor
cells. Blood, 80: 178a, 1992.
50
176.
P. Nahreini and A. Srivastava. Molecular cloning and integration of DNA fragments
in human cells via the inverted terminal repeat hairpins of the adeno-associated virus
2 genome. 4th Parvovirus Workshop. Elsinore, Denmark, 1991.
177.
M.J. Woody, H. Wardhan, N.C. Munshi and A. Srivastava. In vitro transcription of the
human parvovirus B19 inverted terminal repeat (ITR) abolishes translation of the viral
non-structural (NS1) protein. 4th Parvovirus Workshop. Elsinore, Denmark, 1991.
178.
P. Nahreini and A. Srivastava. Site-specific integration of the adeno-associated virus
2 genome into chromosomal DNA of normal human diploid cells. 4th Parvovirus
Workshop. Elsinore, Denmark, 1991.
179.
S.Z. Zhou, C.H. Srivastava, N.C. Munshi and A. Srivastava. Parvovirus B19 replication in
human cord blood cells: A possible mechanism of virus-induced hydrops fetalis. 4th
Parvovirus Workshop. Elsinore, Denmark, 1991.
180.
P. Nahreini, N.C. Munshi, S.Z. Zhou, Q. Li, G. Stamatoyannopoulos and A. Srivastava.
Parvovirus-mediated gene transfer in human cells: Site-specific integration and
expression of the neoR gene. Blood, 78: 207a, 1991.
181.
P. Nahreini, S.H. Larsen and A. Srivastava. Molecular cloning of DNA fragments in
mammalian cells: Adeno-associated virus 2 inverted terminal repeats are novel
cloning vectors. Indiana Branch-American Society for Microbiology Annual Meeting,
Indianapolis, IN, 1990.
182.
M.J. Woody and A. Srivastava. In vitro transcription and translation of the nonstructural (NS1) proteins of the human pathogenic parvovirus B19. Indiana BranchAmerican Society for Microbiology Annual Meeting, Indianapolis, IN, 1990.
183.
N.C. Munshi, M.J. Woody and A. Srivastava. Successful replication of parvovirus B19
in a human megakaryocytic leukemia cell line. Blood, 76: 42a, 1990.
184.
A. Srivastava, E. Bruno, K. van Besien, S. Jackson and R. Hoffman. The human
parvovirus B19 can alter human megakaryocytopoiesis. Clin. Res., 37: 387a, 1989.
185.
P. Nahreini, M.A. Dayton and A. Srivastava. Mechanism of rescue of the adeno
associated virus 2 genome in mortal and immortal human cells. Gerontol., 151a,
1989.
186.
P. Nahreini, M.A. Dayton and A. Srivastava. Mechanism of rescue of the adenoassociated virus 2 genome in mortal and immortal human cells. Indiana BranchAmerican Society for Microbiology Annual Meeting. Indianapolis, IN, 1989.
187.
A. Srivastava and H. Ashktorab. Identification of nuclear proteins that specifically
interact with the adeno-associated virus 2 inverted terminal repeat hairpin DNA.
Indiana Branch-American Society for Microbiology Annual Meeting. Indianapolis, IN,
1989.
188.
C.H. Srivastava, R.J. Samulski, L. Lu, S.H. Larsen and A. Srivastava. Construction of an
infectious recombinant human parvovirus B19. EMBO Workshop - Molecular Biology
of Parvoviruses. Jerusalem, Israel, 1989.
189.
M.J. Woody, S.A. Jackson and A. Srivastava. Structural and functional similarities
between the adeno-associated virus 2 and parvovirus B19 rep proteins. EMBO
Workshop-Molecular Biology of Parvoviruses. Jerusalem, Israel, 1989.
190.
A. Srivastava, M.J. Woody and S.A. Jackson. Parvovirus B19 DNA replication in
human KB cells: Functional similarities between the AAV and B19 rep proteins. Blood,
74: 101a, 1989.
51
191.
P. Nahreini and A. Srivastava. Replication of adenovirus and adeno-associated virus
in young and senescent human diploid fibroblasts. VIIIth International Washington
Spring Symposium, Washington, D.C., 1988.
192.
P. Nahreini and A. Srivastava. Rescue and replication of the adeno-associated virus
genome in mortal and immortal human cells. Indiana Branch-American Society for
Microbiology Annual Meeting, Indianapolis, IN, 1988.
193.
P. Nahreini and A. Srivastava. Rescue and replication of the adeno-associated virus
genome in young and senescent human diploid fibroblasts. Gerontol., 28: 230a, 1988.
194.
A. Srivastava and S. Jackson. Construction of a recombinant human parvovirus B19:
Replication of the viral genome with inverted terminal repeats from the human
adeno-associated virus. Blood, 72: 50a, 1988.
195.
M.A. Dayton and A. Srivastava. Evidence associating augmented nuclease activity
with cellular senescence. Gerontol., 27: 144a, 1987.
196.
Srivastava. G-proteins, trans-membrane
Gerontol., 27: 144a, 1987.
197.
A. Srivastava and L. Lu. B19 Parvovirus replication in highly enriched hematopoietic
progenitor cells from human bone marrow. Blood, 70: 56a, 1987.
198.
A. Srivastava, R.C. Lauer, S. Jackson, R. Hoffman and G.J.K. Tricot. Altered expression
of cellular oncogenes in myelodysplastic syndromes. Blood, 70: 287a, 1987.
199.
A. Srivastava, P. Nahreini, N. Heerema, A. Antony and H.S. Boswell. Ki-ras oncogene
over-expression in a human preleukemic syndrome involving human chromosome 5.
Exp. Hematol., 14: 432, 1986.
200.
A. Srivastava, N.A. Heerema, R.C. Lauer, P. Nahreini, H.S. Boswell, R. Hoffman and
A.C. Antony. Acute promyelocytic leukemia with X;15 translocation: Role of the neu
oncogene. Blood, 68: 266A, 1986.
201.
S. Goldstein, A. Srivastava, K.T. Riabowol and R.J. Shmookler Reis. Genetic
organization and expression in aging human fibroblasts. In Vitro, 21: 14A, 1985.
202.
S. Goldstein, A. Srivastava, K.T. Riabowol and R.J. Shmookler Reis. Cultured human
fibroblasts change their genetic organization and expression during replicative
senescence. Canadian Congress of Biology, University of Western Ontario, London,
Ontario, Canada, 1985.
203.
A. Srivastava, R.J. Shmookler Reis and S. Goldstein. c-Ha-ras-1 proto-oncogene
amplification and expression in senescent human diploid fibroblasts. J. Cell.
Biochem., 8B: 141, 1984.
204.
A. Srivastava, R.J. Shmookler Reis and S. Goldstein. c-Ha-ras-1 proto-oncogene in
cultured human fibroblasts: Amplification and increased transcription during cellular
aging. Clin. Res., 32: 493A, 1984.
205.
A. Srivastava, R.J. Shmookler Reis and S. Goldstein. c-Ha-ras-1 proto-oncogene
amplification and expression during cellular aging in vitro. Fed. Proc., 43: 1886, 1984.
206.
K.I. Berns, N. Muzyczka, R.J. Samulski and A. Srivastava. Symmetry, inversion and selfrepair in adeno-associated virus DNA replication. J. Cell. Biochem., 7B: 76, 1983.
207.
M.J. Modak and A. Srivastava. Reverse transcriptase-associated RNaseH does not
require zinc for catalysis. Fed. Proc., 38: 780, 1979.
52
signaling
and
cellular
senescence.
208.
A. Srivastava and M.J. Modak. Characterization of reverse transcriptase-associated
enzymatic activities. Amer. Assoc. Cancer Res., 20: 248, 1979.
209.
A. Srivastava, A. Antony and T. Ramakrishnan. Site-specific inhibition of Rous
sarcoma virus reverse transcriptase by the copper complexes of isonicotinic acid
hydrazide. Ind. J. Biochem. Biophys., 15: 83, 1978.
210.
A. Srivastava, A. Antony, T. Ramakrishnan, U.S. Nandi. Mechanisms of action of a
new antiviral drug. Ind. J. Biochem. Biophys., 14: 2, 1977.
211.
A. Antony, A. Srivastava, T. Ramakrishnan, U.S. Nandi and W. E. Levinson. Effect of
isonicotinic acid hydrazide-copper complexes on nucleic acid replication. Proc.
Assoc. Microbiol., 15: 9, 1974.
53